MIRA
INFORM REPORT
|
Report Date : |
02.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
CHUGAI PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
2-1-1, Muromachi-nihonbashi, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
08.03.1943 |
|
|
|
|
Legal Form : |
Public Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
6,779 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
-- |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
CHUGAI PHARMACEUTICAL CO., LTD.
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business
Description
|
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical
company. The Company operates in two business segments. The Domestic segment
is engaged in the sale of pharmaceutical products manufactured by the Company
through its nationwide appointed stores. This segment is also involved in the
research, development, transportation and storage of pharmaceutical products,
as well as the provision of literature research services for pharmaceutical
information. The Overseas segment is engaged in the sale of its
pharmaceutical products in oversea markets, such as |
Industry
|
Industry |
Biotechnology and Drugs |
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal
Product Manufacturing |
|
NACE 2002: |
2442 - Manufacture of pharmaceutical
preparations |
|
NAICS 2002: |
325412 - Pharmaceutical Preparation
Manufacturing |
|
|
24421 - Manufacture of medicaments |
|
US SIC 1987: |
2834 - Pharmaceutical Preparations |
Key Executives
|
Significant
Developments
|
|||||||||||||||||||||||||
|
* number of significant developments within the last 12 months |
|
||||||||||||||||||||||||
News
|
Financial
Summary
|
Stock Snapshot
|
1 - Profit &
Loss Item Exchange Rate: USD 1 = JPY 79.69823
2 - Balance Sheet Item Exchange Rate: USD 1 = JPY 76.94
Corporate Overview
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Strategic Initiatives report is created using technology to extract
meaningful insights from analyst reports about a company's strategic projects
and investments. More
about Strategic Initiatives
Strategic Initiatives
|
Partnerships |
|
|
It has three products in Phase III clinical trials, namely, MRA
(Actemra) for Rheumatoid arthritis (new formulation: subcutaneous injection)
and RG484 for Osteoporosis. Its alliance with Roche led to significant
achievements in research and development programs. The company also shares
multiple agreements of product development such as small molecular
collaboration, biotechnology collaboration, concentration on ethical drug
market, oncology unit and the most important being the joint development
program and overseas filing of Actemra.Leadership Position-Oncology and
Antibody DrugThe company is a recognized player in the Japanese
pharmaceutical market. The company’s annual growth in revenues and
operating income averaged over 10% for the last three years. Chugai’s
flagship oncology and antibody drugs secured the highest share of the
domestic market, and its development pipeline is the main source of future
growth and is also one of the richest in Japan. |
|
|
As such GlobalData can accept no liability whatever for actions taken
based on any information that may subsequently prove to be incorrect. Oct 11,
2010Antitope Forms EpiScreen collaboration With ChugaiAntitope Ltd., a
UK-based biotechnology company, has formed a research collaboration with
Chugai Pharmaceuticals Co., Ltd (Chugai) whereby Antitope will apply its
EpiScreen technology to profile the immunogenicity of therapeutic antibodies
developed by Chugai as a part of their research and development program.Matthew
Baker, chief scientific officer and co-founder of Antitope, said: "We
are delighted to be working with Chugai to assist with their drug discovery
programmes. The EpiScreen technology will enable us to assist Chugai by
providing a preclinical assessment of the immunogenicity of candidate
therapeutic antibodies and proteins in order to select leads with low
immunogenicity potential. |
|
|
The company has announced that it will make organizational and
personnel changes, effective October 1, 2010.Feb 18, 2010Chugai Exercise's
Development Rights For GDC-0449 In JapanCuris, a drug development company
involved in development of small molecule drug candidates for cancer
treatment, has said that Chugai Pharmaceutical has exercised its right of
first refusal for the development and commercialization in Japan of GDC-0449,
a Hedgehog pathway inhibitor developed by Genentech, a wholly owned member of
the Roche Group, under an existing agreement with F Hoffmann-La
Roche.GDC-0449 was discovered by Genentech, under the ongoing collaboration
agreement between Genentech and Curis, and was jointly validated through a
series of preclinical studies. Through this partnership, the duo are
responsible for the clinical development and commercialization of GDC-0449.
The company says that it is entitled to receive cash payments upon the
successful achievement of specified clinical development and regulatory
approval milestones, and also royalties accrued from commercialization of
GDC-0449 by Genentech and its sublicensees. |
|
|
Sales and Distribution |
|
|
It intends to continually create innovative pharmaceuticals and to
realize high growth and profit with future products beyond Actemra, and
Avastin. To sustain its position as a leader in the domestic oncology market
and generate strong revenue growth, it intends to establish Avastin, Xeloda
and Herceptin as standards of care. In the field of bone and joint diseases,
it intends to incorporate rapid market penetration strategy for its product
Edirol, approved in January 2011, and to further expand sales of Actemra. In
Japan, the requirement for all-patient registration surveillance for Actemra
was removed last year, which would help to accelerate its market penetration
in 2011. We will focus on providing information backed by the extensive data
obtained from that surveillance to establish Actemra as a first-line
biologic. |
|
|
Overview
Chugai is a Japan-based pharmaceutical company engaged in manufacturing
and marketing pharmaceutical products in Japan and overseas. The company
utilizes leading technologies in biopharmaceutical and molecular targeted drug
discovery theraphy areas for the development of innovative drugs. The
company’s strategic alliance with Roche has led to significant internal
development and it has enhanced additional product development. However,
failure to comply with government regulatory standards, presence of counterfeit
drugs and uncertain R&D outcomes may hinder the company’s ability to earn
revenues and improve the financial condition of the company.
Strengths
A wide product portfolio helps the company in establishing its presence
in the market and in generating more revenue through the captured market. The
company has a broad product range that serves Oncology, Bone and Joint
therapeutics, Renal Disease, and Others. In the area of Oncology, Avastin,
Neutrogin,Herceptin, Rituxan,Xeloda, Tarceva, Kytril and Femara. The product
range in Oncology area contributed to 42.1% of the total revenues in 2010. For
bone and joint diseases, it markets Evista, Alfarol, Actemra and Suvenyl. This
product area contributed to 20% of the total revenues of 2010. Its products for
renal disease include Epogin, Renagel and Oxarol, contributed to 15.3% of the
total revenue. Under others, it markets and distributes Tamiflu, Sigmart,
Pegasys, Rocephin, Cellcept and Copegus. In October 2010, the company developed
an innovative antibody engineering technology that will enable a single
antibody molecule to bind to a target antigen multiple times. The technology
developed applied to Actemra, demonstrated more than a four-fold increase in
the duration of IL-6 receptor blockade. The company expects this technology to
substantially broaden the possibilities for antibody drug discovery. Such wide
product portfolio insulates the company from fall in demand for any particular
product line, thereby giving it a balanced revenue platform.
Strategic alliances with major players in industry have enabled the
company to increase the scope of its business activities and successfully
complement its market leadership position. Its strategic alliance with Roche
and subsequent merger with Nippon Roche enabled Chugai to build a strong
research capabilities and technology platform in the area of biopharmaceuticals
and small molecules. Chugai implemented initiatives to enhance its operations
in research and development, safety management and sales production. Chugai’s
strategic alliance with Roche has significantly boosted its competitiveness in
terms of research, development and marketing. In research and development
(R&D), the company successfully utilized Roche’s global R&D
infrastructure and participated in global clinical studies partnering
Genentech, Inc. of the US. In addition, compounds licensed from the Roche also
have enhanced Chugai’s broad development pipeline. The company also licensed
a growing number of compounds to Roche. In the area of marketing, the
company’s access to the Roche’s efficient global marketing network enabled
Chugai to raise the international competitiveness of its products. These
initiatives produced significant results. Chugai’s three projects including
ED-71 for osteoporosis and MRA (Actemra for US) were approved in Jan 2011and
Jan 2010. The company filed application for MRA (Actemra) as Systemic-onset
juvenile idiopathic arthritis (sJIA). It has three products in Phase III
clinical trials, namely, MRA (Actemra) for Rheumatoid arthritis (new
formulation: subcutaneous injection) and RG484 for Osteoporosis. Its alliance
with Roche led to significant achievements in research and development
programs. The company also shares multiple agreements of product development
such as small molecular collaboration, biotechnology collaboration,
concentration on ethical drug market, oncology unit and the most important
being the joint development program and overseas filing of Actemra.
Leadership Position-Oncology and Antibody Drug
The company is a recognized player in the Japanese pharmaceutical
market. The company’s annual growth in revenues and operating income averaged
over 10% for the last three years. Chugai’s flagship oncology and antibody
drugs secured the highest share of the domestic market, and its development
pipeline is the main source of future growth and is also one of the richest in
Japan. The company is a market leader in domestic oncology and antibody drug
market with a market share of 18.4% and 40.5% as of 2010. It intends to
continually create innovative pharmaceuticals and to realize high growth and
profit with future products beyond Actemra, and Avastin. To sustain its
position as a leader in the domestic oncology market and generate strong
revenue growth, it intends to establish Avastin, Xeloda and Herceptin as
standards of care. In the field of bone and joint diseases, it intends to
incorporate rapid market penetration strategy for its product Edirol, approved
in January 2011, and to further expand sales of Actemra. In Japan, the
requirement for all-patient registration surveillance for Actemra was removed
last year, which would help to accelerate its market penetration in 2011. We
will focus on providing information backed by the extensive data obtained from that
surveillance to establish Actemra as a first-line biologic. Overseas, we will
concentrate on building Actemra into a global blockbuster drug, particularly in
the key US and European markets.
Weaknesses
The company was trading at a price/earnings (P/E) ratio of 17.76 at the
end of fiscal year 2010. This was below the Pharmaceuticals & Healthcare
sector average* of 23.7. A lower than sector average P/E may indicate that the
company may have lower growth prospects compared to other companies in the
sector. Investors may be expecting limited earnings growth in the future
compared to the companies in the sector.
Declining Financial Performance
Chugai reported a decline in its overall financial performance level. It
reported revenues of JPY 379,508.00 million during the fiscal year ended
December 2010, a decrease of 11.53% from 2009. The company's compounded annual
growth rate (CAGR) for revenue was 3.86% during 2006-2010. This was below the
Pharmaceuticals & Healthcare sector average* of 16.53%. The fall in
revenues is attributed to sharp decline in Tamiflu sales as the swine flu
pandemic subsided and also due to the impact of NHI drug price revisions on
Herceptin, Epogin and other products. The decline in sales revenue resulted in
the decreased operational and net profit levels. The operating profit of the
company was JPY 63,758.00 million during the fiscal year 2010, a decrease of
27.95% from 2009. The decrease in operating profit was due to increased
operating costs. Chugai reported operating cost as a percentage to sales ratio
of 83.2% in 2010, as against 79.3% in 2009, followed by administration cost as
a percentage to sales ratio of 25.3% (22.8%). The fall in revenues and
operating profit resulted in decreased bottom line. The net profit of the
company was JPY 41,436.00 million during the fiscal year 2010, a decrease of
26.84% from 2009. The profitability indicators of the company also declined. It
reported operating margin of 16.8% in 2010, as against 20.6% in 2009, followed
by net profit margin 10.9% (13.2%), return on equity 9.2% (13%, return on
capital employed 14.% (20.1%), return on assets 8.1% (10.4%), return on fixed
assets 52.4% (68.4%) and return on working capital of 19.2% in 2010 as against
28.4% in 2009.
Opportunities
Emerging markets offer a strong growth opportunity to the company, which
can leverage its strong brand and product portfolio to take advantage of rapid
growth in these markets. Global pharmaceutical market is expected to around $1
trillion industry for next five years growing at a rate of 8%, mainly due to
the growth in emerging markets such as China and India. Emerging markets bring
new opportunities to pharmaceutical companies, which are registering lower
growth in major markets such as the US and Japan. Driven by rising income and
increased demand for quality healthcare, emerging markets registered the
highest revenue growth. According to industry estimates, global market for
pharmaceuticals estimated at $750 billion, is expected to grow at a CAGR of
3-6% through 2013. With growth in the US slowing; increase in opportunities
across emerging markets is expected to be the growth driver. The emerging
markets are expected to grow at a CAGR of 13-17% through 2014, with China emerging
as the third largest Pharma market by 2011. In 2009, seven emerging markets
contributed to over 50% of this growth. Major therapeutic areas set to
experience growth include oncology, respiratory agents, anti-diabetes,
Angiotensin II Antagonists, HIV antivirals, platelet aggregation inhibitors,
and topical nasal preps. By 2025, 50% of the new patients in high growth areas
including, diabetes and oncology are expected to come from BRIC countries.
Chugai’s extensive research and development activities have enabled it
to develop a strong portfolio of products across various indications. Huge
portfolio of product candidates in development provides significant revenue
generating opportunities for the company as and when these pipeline products
are approved and commercialized. In the oncology area, the company’s product
candidates in development include MRA for pancreatic cancer, gastric cancer,
breast cancer (adjuvant), glioblastoma, glioblastoma (relapsed) and breast
cancer, EPOCH (chemotherapy-induced anemia), RG1415 (pancreatic cancer and
non-small cell lung cancer (first-line treatment)), RG340, TP300 and RG597
(gastric cancer), RG1273 and RG3502 (breast cancer), MRA (pancreatic cancer),
PA799, CKI27 (RG7304) and CIF (RG7167) (solid tumors), WT4869 (myelodysplastic
syndromes), GA101 (RG7159) (non-Hodgkin’s lymphoma) and AF802 (non-small cell
lung cancer). In the bone and joint indications, key product candidates include
MRA for Rheumatoid arthritis (new formulation: subcutaneous injection), RG484
(osteoporosis), SA237 (rheumatoid arthritis). In the area of renal diseases,
R744 is the company’s key product indicated for renal anemia. In the area of
transplant, immunology and infectious diseases the development products include
RG964 and RG442 for compensated liver cirrhosis caused by hepatitis C virus. In
the area of other diseases, CSG452 (RG7201) for type 2 diabetes, RG1678
(schizophrenia), RG1583 (ITM-077) (type 2 diabetes) and RG1450 (Alzheimer’s
disease).
Growing incidence of diabetes would provide new avenues for revenue
growth, as it operates principally in the growing diabetes care market. The
frequency of the occurrence of diabetes among children and adults is increasing.
In the US, diabetes is the most prominent and is the fifth leading cause of
death. It is also common in other areas of the world. In China alone, around
one million people are affected by this disease every year. While India has the
maximum number of cases with 40 million people. Presently, approximately 195
million people are affected by diabetes. It has also been anticipated that 330
million individuals worldwide would be afflicted with diabetes by 2030. Type 2
diabetes mellitus (T2DM) is a disease with the characteristics of increased
blood glucose related with insulin resistance and comparative insulin
deficiency. Of the diagnosed diabetes cases, around 90% are type 2. T2DM
prevalence rates almost doubled between 1990 and 2005. It is increasingly being
diagnosed in children in connection with rising juvenile obesity rates.
Diabetes care is a key focus area for the company.
The company could benefit from its focus on Oncology. Based on the
in-house research, the Oncology therapeutics market was worth $54 billion in
2009 and it is expected to be worth of $60.5 billion in 2010. Recent
developments to treat particular cancer types have driven growth in the market.
Within the oncology therapeutics market - breast, colorectal, lung, prostate,
and pancreatic cancers have the largest market in terms of the number of
patients diagnosed. Antineoplastics, immunostimulating agents, and cytostatic
hormone therapies are driving the highly competitive global oncology
therapeutics market. Also, other factors such as rapid uptake of targeted
therapies in key cancer indications with increased efficacy and reduced
toxicity is expected to contribute to the growth. The analysis of the oncology
therapeutics market indicates that there will be an increase in the market
share of indications such as lung cancer, Non Hodgkin’s lymphoma and breast
cancer by 3%, 1%and 1% respectively in 2016 as compared to their market share
in 2009. It is estimated that there will be a decrease in the market share of
prostate cancer and colorectal cancer by 4% and 1% respectively in 2016. The
prevalence of cancer is expected to double in the coming two decades owing to
the steady increase in the elderly population. Senior citizens already
contribute a great deal to the sales of drugs for most of the age related
cancers like breast cancer, prostate cancer, lung cancer, colorectal cancer,
non-Hodgkin’s lymphoma, melanoma, and brain cancer. The company should
particularly benefit from its focus on Oncology.
Threats
National Health Insurance Reviews
A major threat to company’s sales growth in Japan is the National
Health Insurance price reimbursement reviews made by the government. The drug
must be listed on NHI drug price list to be reimbursed by health insurance providers.
The listed drugs are reviewed biyearly and reimbursement price is aligned
according to a pricing pattern. These biennial NHI reimbursement price reviews
had droved down the price of pharmaceutical products and will have similar
affect in the future. Moreover, it also had substantial outcomes on the sales
of Japanese marketed drugs in current year. NHI price reimbursement reviews in
2008 and 2010 could continue to pose substantial risk to the company’s sales
growth.
Chugai’s manufacturing facilities and clinical or research practices
are subject to government regulations in the respective countries. The company
should ensure that its manufacturing facilities meet the regulatory standards
and are subject to regular inspections. Chugai’s financial position, cash
flows and results of operations may be affected by the cost of regulatory
compliance, including the expenses related to compliance failures. Failure to
comply with present or future regulations related to clinical, laboratory and
manufacturing practices may result in delays in the approval of drugs, product
recalls, and cancellation of the authority to produce or sell the drugs. The
company’s financial condition would be adversely due to its inability in
obtaining or retaining regulatory approvals on a timely basis, as this would
delay the commercialization activities for its products.
Adverse or inconclusive results from preclinical testing or clinical
trials may substantially delay or halt the development of the company's various
product candidates, consequently affecting its timeliness for profitability.
The outcome of clinical trials is always a subject of uncertainty. After the
discovery of a new compound, substantial amount of money and a great deal of
time are required to successfully launch a new product. Moreover, it may become
necessary to discontinue clinical development if the effectiveness of a drug is
not proven as initially expected, or if serious adverse effects arise. In
addition, pharmaceuticals are subject to legal restrictions in each country and
authorization from local regulatory authorities is a prerequisite for a product
launch in every country. It is difficult to accurately foresee when approvals
for a new product can be obtained.
The company’s markets are characterized by intense competition,
evolving industry standards and business models. The demand for its products
depends on the competitive atmosphere, including the timely development and
introduction of new and competitive products and the company’s response to
downward pricing to sustain competition. Further western companies are
intensifying the competition in Japan. The International Conference on
Harmonization (ICH) had relaxed some of its regulations and allowed the Western
pharmaceutical companies to market products without carrying out separate
clinical trials in the Japanese market. Additionally, other foreign companies
are expanding their sales and marketing operations in Japan. Intense
competition in Japan, the company's largest geographical segment could increase
the threat to its market share. The competitors of the company have greater
experience, research and development capabilities, greater manufacturing,
marketing, financial, and managerial resources than the company. Factors
including changes in customer order patterns, changing incentive programs or
competitors’ new products can impact the company’s competitive ability.
Corporate Structure News
|
CHUGAI
PHARMACEUTICAL CO., LTD. |
|
|
|
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Parent |
Basel |
Switzerland |
Biotechnology and Drugs |
47,953.9 |
80,129 |
||
|
Acquisition of PVT Probenverteiltechnik GmbH proposed/announced.See corporate
structure news on Roche Holding Ltd. for details |
|||||||
|
Subsidiary |
Basel |
Switzerland |
Biotechnology and Drugs |
43,781.2 |
80,129 |
|
|
|
Subsidiary |
Mannheim, Baden-Württemberg |
Germany |
Biotechnology and Drugs |
4,424.6 |
12,000 |
|
|
|
Subsidiary |
Ponce, PR |
United States |
Scientific and Technical Instruments |
|
222 |
|
|
|
Subsidiary |
Mannheim, Baden-Württemberg |
Germany |
Chemical Manufacturing |
26.2 |
111 |
|
|
|
Subsidiary |
Mannheim |
Germany |
Biotechnology and Drugs |
0.4 |
20 |
|
|
|
Subsidiary |
Mexico, DF |
Mexico |
Biotechnology and Drugs |
75.0 |
2,000 |
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Biotechnology and Drugs |
1,292.9 |
1,376 |
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sheringham |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Neuilly sur Seine |
France |
Personal and Household Products |
1,921.5 |
1,277 |
|
|
|
Subsidiary |
Grenzach-Wyhlen |
Germany |
Biotechnology and Drugs |
|
1,000 |
|
|
|
Subsidiary |
Mississauga, ON |
Canada |
Biotechnology and Drugs |
637.3 |
700 |
|
|
|
Subsidiary |
Dee Why, NSW |
Australia |
Fish and Livestock |
|
590 |
|
|
|
Subsidiary |
Dee Why, NSW |
Australia |
Biotechnology and Drugs |
483.9 |
560 |
|
|
|
Subsidiary |
Toronto, ON |
Canada |
Business Services |
1.1 |
500 |
|
|
|
Subsidiary |
Sao Paulo, SP |
Brazil |
Biotechnology and Drugs |
|
500 |
|
|
|
Subsidiary |
Isando |
South Africa |
Personal and Household Products |
150.0 |
446 |
|
|
|
Subsidiary |
Burgdorf |
Switzerland |
Medical Equipment and Supplies |
|
355 |
|
|
|
Subsidiary |
Almere |
Netherlands |
Medical Equipment and Supplies |
186.6 |
200 |
|
|
|
Subsidiary |
Wien |
Austria |
Medical Equipment and Supplies |
140.3 |
192 |
|
|
|
Subsidiary |
Fishers, IN |
United States |
Medical Equipment and Supplies |
0.6 |
150 |
|
|
|
Subsidiary |
Portsmouth, NH |
United States |
Medical Equipment and Supplies |
35.4 |
100 |
|
|
|
Subsidiary |
Kiel, Schleswig Holstein |
Germany |
Medical Equipment and Supplies |
|
20 |
|
|
|
Subsidiary |
Verona |
Italy |
Medical Equipment and Supplies |
|
12 |
|
|
|
Subsidiary |
Meylan, Cedex |
France |
Medical Equipment and Supplies |
|
|
|
|
|
Subsidiary |
Makati City |
Philippines |
Biotechnology and Drugs |
73.4 |
300 |
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
60.0 |
300 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
143.3 |
260 |
|
|
|
Subsidiary |
Buenos Aires |
Argentina |
Biotechnology and Drugs |
174.0 |
225 |
|
|
|
Subsidiary |
Bogotá DC |
Colombia |
Personal and Household Products |
293.3 |
200 |
|
|
|
Subsidiary |
Caracas |
Venezuela |
Personal and Household Products |
60.0 |
200 |
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
200 |
|
|
|
Subsidiary |
Prague |
Czech Republic |
Personal and Household Products |
|
200 |
|
|
|
Subsidiary |
Amadora |
Portugal |
Biotechnology and Drugs |
225.9 |
190 |
|
|
|
Subsidiary |
Bruxelles |
Belgium |
Personal and Household Products |
266.8 |
182 |
|
|
|
Subsidiary |
Bangkok |
Thailand |
Personal and Household Products |
82.7 |
180 |
|
|
|
Subsidiary |
Taipei |
Taiwan |
Personal and Household Products |
1.0 |
175 |
|
|
|
Roche
(Magyarország) Gyógyszer- és Vegyianyagkereskedelmi Kft |
Subsidiary |
Budaörs |
Hungary |
Biotechnology and Drugs |
156.5 |
173 |
|
|
Subsidiary |
Wien |
Austria |
Personal and Household Products |
263.0 |
161 |
|
|
|
Subsidiary |
Maroussi |
Greece |
Personal and Household Products |
339.9 |
160 |
|
|
|
Subsidiary |
Reinach |
Switzerland |
Biotechnology and Drugs |
|
160 |
|
|
|
Subsidiary |
Vilvoorde |
Belgium |
Healthcare Facilities |
124.2 |
153 |
|
|
|
Subsidiary |
Woerden |
Netherlands |
Biotechnology and Drugs |
325.2 |
151 |
|
|
|
Subsidiary |
Heredia |
Costa Rica |
Biotechnology and Drugs |
|
150 |
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
|
115 |
|
|
|
Subsidiary |
Hvidovre |
Denmark |
Personal and Household Products |
123.0 |
113 |
|
|
|
Subsidiary |
Montevideo |
Uruguay |
Biotechnology and Drugs |
|
107 |
|
|
|
Subsidiary |
Bogota, Cundinamarca |
Colombia |
Miscellaneous Capital Goods |
90.0 |
100 |
|
|
|
Subsidiary |
Jeddah, Makkah |
Saudi Arabia |
Miscellaneous Capital Goods |
49.0 |
100 |
|
|
|
Subsidiary |
Santiago |
Chile |
Miscellaneous Capital Goods |
46.0 |
100 |
|
|
|
Subsidiary |
Heliopolis |
Egypt |
Food Processing |
46.0 |
100 |
|
|
|
Subsidiary |
Chatuchak, Bangkok |
Thailand |
Biotechnology and Drugs |
43.0 |
100 |
|
|
|
Subsidiary |
Quito |
Ecuador |
Personal and Household Products |
|
90 |
|
|
|
Subsidiary |
Auckland, Penrose |
New Zealand |
Personal and Household Products |
11.0 |
85 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
93.2 |
74 |
|
|
|
Subsidiary |
Oslo |
Norway |
Personal and Household Products |
76.6 |
60 |
|
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
1.0 |
50 |
|
|
|
Subsidiary |
Kulmbach, Bayern |
Germany |
Biotechnology and Drugs |
|
50 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Personal and Household Products |
58.0 |
48 |
|
|
|
Subsidiary |
Paramus, NJ |
United States |
Healthcare Facilities |
0.4 |
13 |
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
60.0 |
10 |
|
|
|
Subsidiary |
Santiago |
Chile |
Biotechnology and Drugs |
|
10 |
|
|
|
Subsidiary |
Panama |
Panama |
Biotechnology and Drugs |
|
8 |
|
|
|
Subsidiary |
Amman |
Jordan |
Food Processing |
|
|
|
|
|
Subsidiary |
Casablanca |
Morocco |
Food Processing |
|
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Chemical Manufacturing |
|
|
|
|
|
Subsidiary |
Petah Tiqwa |
Israel |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Guatemala |
Guatemala |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Guatemala |
Guatemala |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Maharashtra |
India |
Miscellaneous Capital Goods |
|
|
|
|
|
Joint Venture |
Wuxi, Jiangsu |
China |
Chemical Manufacturing |
|
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Shanghai, Shanghai |
China |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Rotkreuz |
Switzerland |
Biotechnology and Drugs |
|
20,000 |
|
|
|
Subsidiary |
South San Francisco, CA |
United States |
Biotechnology and Drugs |
13,418.0 |
11,000 |
|
|
|
Branch |
Vacaville, CA |
United States |
Personal and Household Products |
1,393.0 |
1,000 |
|
|
|
Subsidiary |
O Porriño, Pontevedra |
Spain |
Chemical Manufacturing |
87.7 |
288 |
|
|
|
Subsidiary |
Houston, TX |
United States |
|
|
197 |
|
|
|
Branch |
S San Francisco, CA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Louisville, KY |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Arlington, VA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Gilbert, AZ |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Newtown, PA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Madison, WI |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Oceanside, CA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Dunwoody, GA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Redwood City, CA |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Mahwah, NJ |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Tulsa, OK |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Washington, DC |
United States |
Personal and Household Products |
13.9 |
10 |
|
|
|
Branch |
Hillsboro, OR |
United States |
Biotechnology and Drugs |
|
10 |
|
|
|
Branch |
Southlake, TX |
United States |
Personal and Household Products |
7.0 |
5 |
|
|
|
Branch |
Sacramento, CA |
United States |
Personal and Household Products |
7.0 |
5 |
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
4,686.6 |
6,779 |
|
|
|
Subsidiary |
London |
United Kingdom |
Business Services |
162.8 |
181 |
|
|
|
Subsidiary |
London |
United Kingdom |
Retail (Specialty) |
16.0 |
32 |
|
|
|
Subsidiary |
Puteaux |
France |
Biotechnology and Drugs |
116.1 |
74 |
|
|
|
Joint Venture |
Hwasun, Kyunggi Do |
Korea, Republic of |
Biotechnology and Drugs |
|
60 |
|
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
1.0 |
50 |
|
|
|
Subsidiary |
London |
United Kingdom |
Business Services |
9.4 |
32 |
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
20 |
|
|
|
Joint Venture |
Antony, Cedex |
France |
Biotechnology and Drugs |
111.6 |
17 |
|
|
|
Subsidiary |
New York, NY |
United States |
Personal and Household Products |
|
2 |
|
|
|
Subsidiary |
Kita-Ku, Tokyo |
Japan |
Biotechnology and Drugs |
1,099.9 |
|
|
|
|
Branch |
Frankfurt am Main |
Germany |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Shanghai |
China |
Business Services |
|
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Business Services |
|
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Business Services |
|
|
|
|
|
Subsidiary |
Kazo City |
Japan |
Miscellaneous Transportation |
|
|
|
|
|
Subsidiary |
Gotemba City |
Japan |
Business Services |
|
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Business Services |
|
|
|
|
|
Subsidiary |
Nutley, NJ |
United States |
Biotechnology and Drugs |
3,750.0 |
6,600 |
|
|
|
Subsidiary |
Palo Alto, CA |
United States |
Business Services |
|
1,000 |
|
|
|
Subsidiary |
Boulder, CO |
United States |
Biotechnology and Drugs |
53.1 |
325 |
|
|
|
Subsidiary |
Florence, SC |
United States |
Biotechnology and Drugs |
32.0 |
300 |
|
|
|
Branch |
Nutley, NJ |
United States |
Personal and Household Products |
41.8 |
30 |
|
|
|
Branch |
St Peters, MO |
United States |
Biotechnology and Drugs |
15.2 |
16 |
|
|
|
Branch |
New York, NY |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Piscataway, NJ |
United States |
Personal and Household Products |
20.9 |
15 |
|
|
|
Branch |
Newark, NJ |
United States |
Retail (Drugs) |
1.8 |
10 |
|
|
|
Branch |
Rockledge, FL |
United States |
Biotechnology and Drugs |
|
10 |
|
|
|
Branch |
Middletown, DE |
United States |
Biotechnology and Drugs |
|
10 |
|
|
|
Branch |
Middletown, DE |
United States |
Biotechnology and Drugs |
|
10 |
|
|
|
Branch |
Nutley, NJ |
United States |
Schools |
|
8 |
|
|
|
Branch |
Wichita, KS |
United States |
Healthcare Facilities |
1.2 |
6 |
|
|
|
Branch |
Totowa, NJ |
United States |
Printing Services |
1.0 |
5 |
|
|
|
Branch |
Gary, WV |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Wilmington, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Newark, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Camden, OH |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Eaton, OH |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Smyrna, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Moorefield, WV |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Durham, NC |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Seaford, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Dover, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Greensburg, IN |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Aurora, NC |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Northfork, WV |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Tucson, AZ |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Lewisville, TX |
United States |
Healthcare Facilities |
0.6 |
4 |
|
|
|
Branch |
Providence, RI |
United States |
Personal and Household Products |
4.2 |
3 |
|
|
|
Branch |
Metropolis, IL |
United States |
Biotechnology and Drugs |
|
3 |
|
|
|
Branch |
Sidney, OH |
United States |
Biotechnology and Drugs |
|
3 |
|
|
|
Subsidiary |
Indianapolis, IN |
United States |
Scientific and Technical Instruments |
42,041.0 |
4,200 |
|
|
|
Unit |
Branchburg, NJ |
United States |
Biotechnology and Drugs |
|
700 |
|
|
|
Unit |
Pleasanton, CA |
United States |
Biotechnology and Drugs |
144.9 |
500 |
|
|
|
Unit |
Ponce, PR |
United States |
Biotechnology and Drugs |
|
230 |
|
|
|
Branch |
Birch Run, MI |
United States |
Medical Equipment and Supplies |
3.9 |
12 |
|
|
|
Branch |
Carmel, IN |
United States |
Personal Services |
|
6 |
|
|
|
Branch |
Washington, DC |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
|
Branch |
Fishers, IN |
United States |
Medical Equipment and Supplies |
1.0 |
3 |
|
|
|
Division |
Indianapolis, IN |
United States |
Business Services |
|
|
|
|
|
Subsidiary |
Madison, WI |
United States |
Biotechnology and Drugs |
|
121 |
|
|
|
Subsidiary |
Waldkraiburg |
Germany |
Business Services |
|
6 |
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
350.0 |
1,800 |
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Commercial Banks |
|
1,604 |
|
|
|
Subsidiary |
México, D.F. |
Mexico |
Biotechnology and Drugs |
675.1 |
1,415 |
|
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
787.9 |
1,300 |
|
|
|
Subsidiary |
Tucson, AZ |
United States |
Healthcare Facilities |
238.2 |
1,300 |
|
|
|
Acquisition of mtm laboratories AG proposed/announced.See corporate
structure news on Roche Holding Ltd. for details |
|||||||
|
Subsidiary |
Sunnyvale, CA |
United States |
Biotechnology and Drugs |
7.4 |
69 |
|
|
|
Subsidiary |
Illkirch-Graffenstaden |
France |
Medical Equipment and Supplies |
20.9 |
34 |
|
|
|
Subsidiary |
Madrid |
Spain |
Biotechnology and Drugs |
1,000.1 |
1,264 |
|
|
|
Subsidiary |
Grenzach-Wyhlen, Baden-Württemberg |
Germany |
Biotechnology and Drugs |
1,903.9 |
1,200 |
|
|
|
Subsidiary |
São Paulo , São Paulo |
Brazil |
Chemical Manufacturing |
350.0 |
1,000 |
|
|
|
Subsidiary |
Mexico City, Distrito Federal |
Mexico |
Chemical Manufacturing |
4.0 |
1,000 |
|
|
|
Subsidiary |
Maslak, Istanbul |
Turkey |
Biotechnology and Drugs |
350.0 |
750 |
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
150.0 |
750 |
|
|
|
Subsidiary |
Meylan |
France |
Personal and Household Products |
495.9 |
749 |
|
|
|
Subsidiary |
Sant Cugat Del Valles, Barcelona |
Spain |
Medical Equipment and Supplies |
520.7 |
706 |
|
|
|
Subsidiary |
Monza, Monza E Brianza |
Italy |
Biotechnology and Drugs |
586.1 |
576 |
|
|
|
Subsidiary |
Branchburg, NJ |
United States |
Medical Equipment and Supplies |
161.0 |
500 |
|
|
|
Subsidiary |
Burgess Hill |
United Kingdom |
Business Services |
348.6 |
484 |
|
|
|
Subsidiary |
Burgess Hill |
United Kingdom |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Medical Equipment and Supplies |
|
|
|
|
|
Subsidiary |
Ricardo Rojas, Buenos Aires |
Argentina |
Biotechnology and Drugs |
318.8 |
400 |
|
|
|
Subsidiary |
Laval, QC |
Canada |
Scientific and Technical Instruments |
217.7 |
400 |
|
|
|
Subsidiary |
Ponce |
Puerto Rico |
Personal and Household Products |
200.0 |
350 |
|
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Biotechnology and Drugs |
61.6 |
350 |
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
300 |
|
|
|
Subsidiary |
Co Clare |
Ireland |
Biotechnology and Drugs |
136.0 |
239 |
|
|
|
Subsidiary |
Gaithersburg, MD |
United States |
Scientific and Technical Instruments |
29.0 |
206 |
|
|
|
Subsidiary |
Witney |
United Kingdom |
Scientific and Technical Instruments |
|
|
|
|
|
Subsidiary |
Brussels |
Belgium |
Biotechnology and Drugs |
236.4 |
205 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
217.9 |
200 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
107.1 |
200 |
|
|
|
Subsidiary |
Branford, CT |
United States |
Biotechnology and Drugs |
1.8 |
180 |
|
|
|
Subsidiary |
Castle Hill, NSW |
Australia |
Healthcare Facilities |
29.3 |
172 |
|
|
|
Subsidiary |
Lima |
Peru |
Personal and Household Products |
|
170 |
|
|
|
Subsidiary |
Stockholm |
Sweden |
Personal and Household Products |
158.8 |
137 |
|
|
|
Subsidiary |
Hvidovre |
Denmark |
Personal and Household Products |
59.6 |
122 |
|
|
|
Subsidiary |
Amadora, Amadora |
Portugal |
Personal and Household Products |
71.5 |
121 |
|
|
|
Subsidiary |
Petaling Jaya, Selangor |
Malaysia |
Healthcare Facilities |
31.2 |
120 |
|
|
|
Subsidiary |
Espoo |
Finland |
Personal and Household Products |
103.4 |
100 |
|
|
|
Subsidiary |
Bromma |
Sweden |
Medical Equipment and Supplies |
61.1 |
100 |
|
|
|
Subsidiary |
Santo Domingo |
Dominican Republic |
Personal and Household Products |
54.0 |
100 |
|
|
|
Subsidiary |
Hamilton |
Bermuda |
Personal and Household Products |
54.0 |
100 |
|
|
|
Subsidiary |
New Territories, New Territories |
Hong Kong |
Healthcare Facilities |
54.0 |
100 |
|
|
|
Subsidiary |
Taipei |
Taiwan |
Medical Equipment and Supplies |
1.0 |
100 |
|
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
100 |
|
|
|
Subsidiary |
Ho Chi Minh City |
Viet Nam |
Food Processing |
52.0 |
95 |
|
|
|
Subsidiary |
Hong Kong |
Hong Kong |
Biotechnology and Drugs |
1.0 |
80 |
|
|
|
Subsidiary |
Maharashtra |
India |
Healthcare Facilities |
1.0 |
80 |
|
|
|
Subsidiary |
Berlin, Berlin |
Germany |
Biotechnology and Drugs |
7.5 |
73 |
|
|
|
Subsidiary |
Oslo, Oslo |
Norway |
Biotechnology and Drugs |
59.2 |
71 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Healthcare Facilities |
24.7 |
70 |
|
|
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
47.0 |
65 |
|
|
|
Subsidiary |
Auckland |
New Zealand |
Biotechnology and Drugs |
1.5 |
48 |
|
|
|
Subsidiary |
Madison, WI |
United States |
Software and Programming |
|
47 |
|
|
|
Subsidiary |
Toronto, ON |
Canada |
Biotechnology and Drugs |
|
41 |
|
|
|
Subsidiary |
Ayr, ON |
Canada |
Chemical Manufacturing |
31.0 |
35 |
|
|
|
Subsidiary |
Montvale, NJ |
United States |
Biotechnology and Drugs |
9.3 |
9 |
|
|
|
Subsidiary |
Carmel, IN |
United States |
Biotechnology and Drugs |
0.7 |
9 |
|
|
|
Subsidiary |
Bielefeld |
Germany |
|
13.7 |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Healthcare Facilities |
3.9 |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Biotechnology and Drugs |
0.0 |
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Hamilton |
Bermuda |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Tallinn |
Estonia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Vilnius |
Lithuania |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Bucharest |
Romania |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Belgrade |
Serbia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Ljubljana |
Slovenia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Esentepe, Istanbul |
Turkey |
Healthcare Facilities |
|
|
|
|
|
Subsidiary |
Tegucigalpa |
Honduras |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Maroussi |
Greece |
Healthcare Facilities |
|
|
|
|
|
Subsidiary |
Graz |
Austria |
Healthcare Facilities |
|
|
|
|
|
Subsidiary |
Cuajimalpa, Federal District |
Mexico |
Healthcare Facilities |
|
|
|
|
|
Subsidiary |
Lima |
Peru |
Medical Equipment and Supplies |
|
|
|
|
|
Subsidiary |
Basel |
Switzerland |
Business Services |
|
|
|
|
|
Subsidiary |
Rosny sous Bois |
France |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Halifax, NS |
Canada |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Dhaka |
Bangladesh |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Managua |
Nicaragua |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
San Salvador |
El Salvador |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Schlieren |
Switzerland |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Panama |
Panama |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Shanghai |
China |
Business Services |
|
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Kiev |
Ukraine |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Strasbourg Cédex |
France |
Business Services |
|
|
|
|
|
Subsidiary |
Sarajevo |
Bosnia and Herzegovina |
Biotechnology and Drugs |
|
|
|
|
|
Executives Report
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Developments
|
|
|
Annual Income Statement
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Sales |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
Total Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
|
|
|
|
|
|
|
Cost of Revenue |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Cost of Revenue, Total |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Gross Profit |
2,710.3 |
2,472.9 |
2,521.9 |
1,933.4 |
1,762.1 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
554.9 |
485.6 |
478.2 |
441.9 |
336.7 |
|
Labor & Related Expense |
470.4 |
428.4 |
391.5 |
328.0 |
267.0 |
|
Advertising Expense |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Total Selling/General/Administrative Expenses |
1,226.1 |
1,095.2 |
1,048.6 |
919.9 |
714.7 |
|
Research & Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Depreciation |
- |
- |
- |
- |
20.3 |
|
Depreciation/Amortization |
- |
- |
- |
- |
20.3 |
|
Restructuring Charge |
0.9 |
-5.5 |
13.1 |
5.2 |
12.9 |
|
Impairment-Assets Held for Use |
10.7 |
3.9 |
2.3 |
3.4 |
2.8 |
|
Impairment-Assets Held for Sale |
3.2 |
31.5 |
-78.1 |
13.2 |
-3.1 |
|
Other Unusual Expense (Income) |
77.2 |
-0.1 |
0.0 |
-57.9 |
0.3 |
|
Unusual Expense (Income) |
91.9 |
29.8 |
-62.8 |
-36.1 |
12.8 |
|
Other, Net |
- |
- |
- |
- |
0.0 |
|
Other Operating Expenses, Total |
- |
- |
- |
- |
0.0 |
|
Total Operating Expense |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
2,374.3 |
|
|
|
|
|
|
|
|
Operating Income |
691.4 |
724.7 |
945.2 |
534.8 |
553.6 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
Interest Expense, Net Non-Operating |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
Interest Income -
Non-Operating |
4.8 |
3.6 |
6.9 |
15.6 |
11.4 |
|
Investment Income -
Non-Operating |
12.9 |
12.5 |
-9.8 |
67.8 |
8.4 |
|
Interest/Investment Income - Non-Operating |
17.7 |
16.2 |
-2.9 |
83.4 |
19.8 |
|
Interest Income (Expense) - Net Non-Operating Total |
17.6 |
16.1 |
-3.1 |
82.1 |
18.3 |
|
Gain (Loss) on Sale of Assets |
-0.1 |
0.2 |
2.8 |
-14.5 |
-16.5 |
|
Other Non-Operating Income (Expense) |
8.0 |
7.2 |
10.3 |
8.0 |
8.7 |
|
Other, Net |
8.0 |
7.2 |
10.3 |
8.0 |
8.7 |
|
Income Before Tax |
716.9 |
748.3 |
955.1 |
610.4 |
564.1 |
|
|
|
|
|
|
|
|
Total Income Tax |
261.7 |
263.1 |
333.1 |
215.4 |
208.4 |
|
Income After Tax |
455.2 |
485.2 |
622.1 |
394.9 |
355.7 |
|
|
|
|
|
|
|
|
Minority Interest |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
-15.5 |
|
Net Income Before Extraord Items |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
Net Income |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
|
|
|
|
|
|
|
Miscellaneous Earnings Adjustment |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Total Adjustments to Net Income |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Common Excl Extraord Items |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
544.2 |
544.2 |
544.5 |
544.8 |
547.0 |
|
Basic EPS Excl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Basic/Primary EPS Incl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
442.1 |
472.0 |
604.9 |
379.8 |
340.2 |
|
Diluted Weighted Average Shares |
544.4 |
544.3 |
544.6 |
545.0 |
547.6 |
|
Diluted EPS Excl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Diluted EPS Incl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dividends per Share - Common Stock Primary Issue |
0.50 |
0.46 |
0.43 |
0.33 |
0.25 |
|
Gross Dividends - Common Stock |
273.1 |
247.9 |
232.6 |
179.1 |
138.8 |
|
Interest Expense, Supplemental |
0.1 |
0.0 |
0.2 |
1.3 |
1.5 |
|
Depreciation, Supplemental |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Total Special Items |
92.0 |
29.6 |
-65.6 |
-21.6 |
29.3 |
|
Normalized Income Before Tax |
808.9 |
777.9 |
889.6 |
588.8 |
593.4 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
33.6 |
10.4 |
-22.9 |
-7.6 |
10.8 |
|
Inc Tax Ex Impact of Sp Items |
295.3 |
273.5 |
310.2 |
207.8 |
219.2 |
|
Normalized Income After Tax |
513.7 |
504.4 |
579.4 |
381.0 |
374.2 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
500.5 |
491.2 |
562.2 |
365.8 |
358.7 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.66 |
|
Diluted Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.65 |
|
Advertising Expense, Supplemental |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Research & Development Exp, Supplemental |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Reported Operating Profit |
783.3 |
754.5 |
882.4 |
498.7 |
566.4 |
|
Reported Ordinary Profit |
797.8 |
741.4 |
965.6 |
553.8 |
574.8 |
|
Normalized EBIT |
783.4 |
754.5 |
882.5 |
498.7 |
566.4 |
|
Normalized EBITDA |
982.9 |
959.4 |
1,090.8 |
692.9 |
693.0 |
|
Interest Cost - Domestic |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Service Cost - Domestic |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Prior Service Cost - Domestic |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
-6.4 |
|
Expected Return on Assets - Domestic |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Actuarial Gains and Losses - Domestic |
7.3 |
10.2 |
12.2 |
-1.3 |
-4.6 |
|
Transition Costs - Domestic |
- |
- |
- |
1.0 |
- |
|
Other Pension, Net - Domestic |
0.3 |
- |
0.6 |
- |
5.6 |
|
Domestic Pension Plan Expense |
37.4 |
38.0 |
36.5 |
19.0 |
16.3 |
|
Defined Contribution Expense - Domestic |
10.6 |
9.5 |
8.6 |
7.3 |
6.3 |
|
Total Pension Expense |
48.0 |
47.5 |
45.1 |
26.3 |
22.6 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
Total Plan Interest Cost |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Total Plan Service Cost |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Total Plan Expected Return |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Total Plan Other Expense |
0.3 |
- |
0.6 |
- |
5.6 |
|
|
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
76.94 |
81.105 |
93.095 |
90.65 |
111.715 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Cash & Equivalents |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
654.9 |
|
Short Term Invsestments |
792.8 |
736.1 |
560.3 |
603.6 |
586.7 |
|
Cash and Short Term Investments |
2,185.6 |
1,675.7 |
1,709.4 |
1,384.3 |
1,241.7 |
|
Accounts Receivable -
Trade, Gross |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
957.9 |
|
Provision for Doubtful
Accounts |
0.0 |
-0.1 |
-0.4 |
-0.7 |
-0.5 |
|
Trade Accounts Receivable - Net |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
957.4 |
|
Total Receivables, Net |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
957.4 |
|
Inventories - Finished Goods |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
- |
|
Inventories - Work In Progress |
0.3 |
0.2 |
0.1 |
0.6 |
- |
|
Inventories - Raw Materials |
230.3 |
190.1 |
224.8 |
187.4 |
- |
|
Total Inventory |
1,364.5 |
1,293.2 |
995.1 |
868.6 |
494.0 |
|
Deferred Income Tax - Current Asset |
295.6 |
245.7 |
226.2 |
240.9 |
183.2 |
|
Other Current Assets |
164.2 |
153.2 |
181.5 |
109.2 |
75.9 |
|
Other Current Assets, Total |
459.8 |
398.9 |
407.7 |
350.1 |
259.1 |
|
Total Current Assets |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
2,952.2 |
|
|
|
|
|
|
|
|
Buildings |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
969.2 |
|
Land/Improvements |
132.3 |
122.0 |
106.3 |
109.6 |
88.9 |
|
Machinery/Equipment |
1,643.3 |
1,572.2 |
1,306.4 |
1,224.9 |
915.2 |
|
Construction in
Progress |
35.3 |
24.8 |
16.4 |
60.5 |
107.3 |
|
Other
Property/Plant/Equipment |
0.8 |
0.6 |
0.2 |
0.0 |
- |
|
Property/Plant/Equipment - Gross |
3,371.5 |
3,271.5 |
2,763.0 |
2,751.5 |
2,080.6 |
|
Accumulated Depreciation |
-2,293.6 |
-2,187.0 |
-1,756.9 |
-1,666.7 |
-1,252.6 |
|
Property/Plant/Equipment - Net |
1,077.9 |
1,084.4 |
1,006.1 |
1,084.9 |
828.0 |
|
Intangibles, Net |
25.5 |
29.1 |
34.8 |
34.3 |
33.3 |
|
LT Investment - Affiliate Companies |
0.8 |
0.7 |
- |
- |
- |
|
LT Investments - Other |
82.8 |
92.8 |
103.7 |
158.7 |
150.7 |
|
Long Term Investments |
83.6 |
93.5 |
103.7 |
158.7 |
150.7 |
|
Note Receivable - Long Term |
0.1 |
0.2 |
0.3 |
0.5 |
0.6 |
|
Deferred Income Tax - Long Term Asset |
182.4 |
184.2 |
156.8 |
134.6 |
80.5 |
|
Other Long Term Assets |
112.9 |
106.2 |
86.5 |
67.1 |
62.9 |
|
Other Long Term Assets, Total |
295.2 |
290.4 |
243.3 |
201.6 |
143.3 |
|
Total Assets |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
4,108.1 |
|
|
|
|
|
|
|
|
Accounts Payable |
225.5 |
240.3 |
368.0 |
317.3 |
155.1 |
|
Accrued Expenses |
335.9 |
265.8 |
354.1 |
281.6 |
210.6 |
|
Notes Payable/Short Term Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Current Portion - Long Term Debt/Capital Leases |
- |
- |
0.1 |
0.0 |
3.1 |
|
Income Taxes Payable |
184.0 |
45.4 |
237.8 |
125.5 |
146.1 |
|
Other Payables |
102.5 |
73.2 |
70.9 |
77.8 |
46.6 |
|
Deferred Income Tax - Current Liability |
- |
- |
- |
0.0 |
0.0 |
|
Other Current Liabilities |
46.6 |
48.4 |
48.4 |
63.9 |
63.3 |
|
Other Current liabilities, Total |
333.1 |
166.9 |
357.1 |
267.3 |
256.0 |
|
Total Current Liabilities |
894.4 |
672.9 |
1,079.3 |
866.2 |
624.7 |
|
|
|
|
|
|
|
|
Long Term Debt |
- |
- |
- |
- |
0.0 |
|
Capital Lease Obligations |
- |
- |
0.1 |
0.0 |
- |
|
Total Long Term Debt |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
|
Total Debt |
0.0 |
0.0 |
0.2 |
0.0 |
3.1 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
1.4 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Deferred Income Tax |
1.4 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Minority Interest |
15.7 |
16.8 |
19.2 |
18.2 |
19.9 |
|
Reserves |
2.3 |
0.0 |
- |
- |
- |
|
Pension Benefits - Underfunded |
43.2 |
41.0 |
37.3 |
31.5 |
29.0 |
|
Other Long Term Liabilities |
25.7 |
8.8 |
20.4 |
0.8 |
0.9 |
|
Other Liabilities, Total |
71.3 |
49.8 |
57.7 |
32.3 |
29.9 |
|
Total Liabilities |
982.7 |
739.5 |
1,156.3 |
916.7 |
674.6 |
|
|
|
|
|
|
|
|
Common Stock |
948.3 |
899.6 |
783.8 |
804.9 |
653.0 |
|
Common Stock |
948.3 |
899.6 |
783.8 |
804.9 |
653.0 |
|
Additional Paid-In Capital |
1,219.5 |
1,153.9 |
1,002.7 |
1,027.5 |
831.9 |
|
Retained Earnings (Accumulated Deficit) |
4,412.2 |
4,039.7 |
3,308.3 |
2,989.6 |
2,220.8 |
|
Treasury Stock - Common |
-471.3 |
-447.0 |
-389.6 |
-388.0 |
-314.3 |
|
Unrealized Gain (Loss) |
10.9 |
16.5 |
17.6 |
14.9 |
24.7 |
|
Translation Adjustment |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
17.4 |
|
Other Equity, Total |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
17.4 |
|
Total Equity |
5,950.9 |
5,524.1 |
4,650.0 |
4,362.0 |
3,433.5 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.6 |
4,108.1 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
Treasury Shares - Common Stock Primary Issue |
15.5 |
15.5 |
15.5 |
14.9 |
14.8 |
|
Employees |
6,779 |
6,709 |
6,485 |
6,383 |
6,257 |
|
Number of Common Shareholders |
49,522 |
50,418 |
55,513 |
44,372 |
45,416 |
|
Total Long Term Debt, Supplemental |
2.0 |
1.8 |
1.6 |
- |
3.1 |
|
Long Term Debt Maturing within 1 Year |
- |
- |
- |
- |
3.1 |
|
Long Term Debt Matur. in Year 6 & Beyond |
2.0 |
1.8 |
1.6 |
- |
0.0 |
|
Total Capital Leases, Supplemental |
0.5 |
0.4 |
0.2 |
- |
- |
|
Capital Lease Payments Due in Year 1 |
0.3 |
0.2 |
0.1 |
- |
- |
|
Capital Lease Payments Due in Year 2 |
0.2 |
0.1 |
0.0 |
- |
- |
|
Capital Lease Payments Due in Year 3 |
0.0 |
0.0 |
0.0 |
- |
- |
|
Capital Lease Payments Due in Year 4 |
0.0 |
0.0 |
0.0 |
- |
- |
|
Capital Lease Payments Due in 2-3 Years |
0.2 |
0.2 |
0.1 |
- |
- |
|
Capital Lease Payments Due in 4-5 Years |
0.0 |
0.0 |
0.0 |
- |
- |
|
Cap. Lease Pymts. Due in Year 6 & Beyond |
0.0 |
0.0 |
0.0 |
- |
- |
|
Pension Obligation - Domestic |
871.3 |
816.3 |
702.0 |
695.7 |
550.3 |
|
Plan Assets - Domestic |
811.6 |
771.9 |
649.2 |
640.6 |
561.5 |
|
Funded Status - Domestic |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Total Funded Status |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
Prepaid Benefits - Domestic |
0.0 |
3.1 |
2.8 |
3.0 |
2.5 |
|
Accrued Liabilities - Domestic |
-33.8 |
-32.0 |
-29.1 |
-23.0 |
-23.3 |
|
Other Assets, Net - Domestic |
25.9 |
15.6 |
26.5 |
35.0 |
-32.0 |
|
Net Assets Recognized on Balance Sheet |
-7.9 |
-13.3 |
0.2 |
15.0 |
-52.8 |
|
Total Plan Obligations |
871.3 |
816.3 |
702.0 |
695.7 |
550.3 |
|
Total Plan Assets |
811.6 |
771.9 |
649.2 |
640.6 |
561.5 |
|
|
|
Annual Cash
Flows |
|
Financials in:
USD (mil) |
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
716.8 |
748.2 |
955.1 |
610.3 |
564.1 |
|
Depreciation |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Depreciation/Depletion |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Unusual Items |
72.1 |
1.6 |
-0.1 |
6.9 |
3.5 |
|
Other Non-Cash Items |
-3.2 |
-6.3 |
-1.4 |
-23.3 |
-23.8 |
|
Non-Cash Items |
69.0 |
-4.7 |
-1.6 |
-16.4 |
-20.3 |
|
Accounts Receivable |
29.6 |
89.9 |
-138.5 |
-24.2 |
-10.7 |
|
Inventories |
-23.5 |
-144.8 |
-144.0 |
-247.2 |
52.4 |
|
Accounts Payable |
-24.5 |
-167.2 |
57.1 |
118.9 |
-90.9 |
|
Taxes Payable |
24.2 |
-43.3 |
47.5 |
-19.7 |
9.6 |
|
Other Operating Cash Flow |
-117.9 |
-505.6 |
-274.0 |
-236.0 |
-118.3 |
|
Changes in Working Capital |
-112.1 |
-771.0 |
-452.0 |
-408.3 |
-157.9 |
|
Cash from Operating Activities |
873.2 |
177.4 |
709.9 |
379.9 |
512.5 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
-191.9 |
|
Capital Expenditures |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
-191.9 |
|
Sale of Fixed Assets |
0.2 |
1.0 |
3.5 |
4.1 |
1.6 |
|
Sale/Maturity of Investment |
1,737.4 |
1,617.8 |
1,470.1 |
1,957.3 |
2,073.9 |
|
Purchase of Investments |
-1,786.6 |
-1,694.4 |
-1,518.7 |
-1,854.4 |
-1,947.5 |
|
Other Investing Cash Flow |
0.1 |
0.1 |
0.2 |
0.3 |
0.1 |
|
Other Investing Cash Flow Items, Total |
-48.9 |
-75.5 |
-44.8 |
107.4 |
128.1 |
|
Cash from Investing Activities |
-189.9 |
-230.0 |
-216.4 |
-136.6 |
-63.8 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
-12.9 |
|
Financing Cash Flow Items |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
-12.9 |
|
Cash Dividends Paid - Common |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
-154.0 |
|
Total Cash Dividends Paid |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
-154.0 |
|
Common Stock, Net |
0.0 |
-0.1 |
-12.0 |
-0.7 |
-233.7 |
|
Issuance (Retirement) of Stock, Net |
0.0 |
-0.1 |
-12.0 |
-0.7 |
-233.7 |
|
Long Term Debt
Reduction |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Long Term Debt, Net |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Issuance (Retirement) of Debt, Net |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Cash from Financing Activities |
-308.0 |
-262.6 |
-237.7 |
-177.6 |
-400.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
-7.2 |
-18.9 |
-1.4 |
-95.4 |
-2.5 |
|
Net Change in Cash |
368.0 |
-334.1 |
254.4 |
-29.7 |
45.8 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
817.4 |
1,076.2 |
754.7 |
713.0 |
580.2 |
|
Net Cash - Ending Balance |
1,185.4 |
742.0 |
1,009.2 |
683.3 |
626.0 |
|
Cash Interest Paid |
0.1 |
0.1 |
0.2 |
1.3 |
1.5 |
|
Cash Taxes Paid |
148.2 |
442.7 |
257.2 |
291.0 |
176.2 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Sales |
4,562.5 |
4,278.0 |
4,476.7 |
3,112.7 |
2,827.1 |
|
Other operating revenue |
124.2 |
45.0 |
105.1 |
- |
- |
|
Revenue on Patent |
- |
- |
- |
49.3 |
100.7 |
|
Total Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
|
|
|
|
|
|
|
Cost of Sales |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Rsv-Return Good Adj |
- |
- |
- |
- |
0.0 |
|
Sales promotion expenses |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Payrolls & Bonuses |
399.6 |
366.7 |
325.6 |
286.2 |
231.5 |
|
Depreciaiton |
- |
- |
- |
- |
20.3 |
|
Provision for bonuses |
40.8 |
31.0 |
36.6 |
25.7 |
22.9 |
|
Provision for directors' bonuses |
- |
- |
- |
- |
1.7 |
|
Periodic retirement benefit costs |
30.0 |
30.8 |
29.4 |
16.2 |
10.2 |
|
Reserve for directors retire. benefits |
- |
- |
- |
- |
0.8 |
|
Research&Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Other general expenses |
554.9 |
485.6 |
478.2 |
441.9 |
336.7 |
|
SP Co-Development Settlement |
- |
- |
0.0 |
-61.3 |
0.0 |
|
SP Subsidy Income |
0.0 |
-0.6 |
0.0 |
-4.8 |
0.0 |
|
SP Sales Right License |
- |
- |
- |
- |
0.0 |
|
SP Restructuring Liquidate Gain |
0.0 |
-5.5 |
0.0 |
- |
0.0 |
|
SP G Extinguishment of tie-in stocks |
- |
0.0 |
-0.3 |
0.0 |
- |
|
SP Impairment Loss |
1.8 |
0.5 |
0.3 |
7.2 |
0.3 |
|
SP Restructuring expenses |
0.9 |
0.0 |
13.1 |
5.2 |
12.9 |
|
SP Periodic retirement benefit costs |
- |
- |
0.0 |
1.0 |
0.0 |
|
SP Provision for environmental measures |
3.5 |
0.0 |
- |
- |
- |
|
SP L on Adjust. for Chan. of Acct. Asset |
12.6 |
0.0 |
- |
- |
- |
|
SP Loss on disaster |
59.3 |
0.0 |
- |
- |
- |
|
SP L on valuation of golf club membershi |
0.1 |
0.0 |
- |
- |
- |
|
SP Loss Val Inv.Sec |
2.7 |
0.0 |
0.1 |
0.2 |
0.0 |
|
NOP G on valuation of derivatives |
- |
0.0 |
-78.3 |
0.0 |
-3.1 |
|
NOP Loss Retire FixAsset |
8.3 |
2.4 |
2.3 |
3.4 |
2.8 |
|
NOP L on valuation of derivatives |
0.4 |
31.5 |
0.0 |
13.0 |
0.0 |
|
NOP L on abandonment of fixed assets |
2.4 |
1.5 |
- |
- |
- |
|
Total Operating Expense |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
2,374.3 |
|
|
|
|
|
|
|
|
SP Gain Sale Assets |
0.0 |
0.2 |
2.8 |
4.1 |
0.0 |
|
SP Gain Sale Inv.Secs. |
0.0 |
1.1 |
0.0 |
- |
0.0 |
|
SP Gain Settlement of Affiliates |
- |
- |
- |
0.0 |
2.5 |
|
SP Loss Sale Fixed Assets |
-0.1 |
0.0 |
0.0 |
-0.1 |
0.0 |
|
SP Loss Sale Inv.Secs. |
0.0 |
0.0 |
0.0 |
- |
- |
|
NOP Interest Income |
4.8 |
3.6 |
6.9 |
15.6 |
11.4 |
|
NOP Dividend Income |
1.5 |
1.5 |
1.2 |
4.1 |
0.8 |
|
NOP Dividends income of life insurance |
4.3 |
0.0 |
0.0 |
3.2 |
2.7 |
|
NOP Exchange Gain |
7.1 |
10.0 |
0.0 |
60.5 |
4.9 |
|
NOP Patent Income |
- |
- |
- |
- |
0.0 |
|
NOP Other Income |
11.7 |
12.1 |
14.3 |
12.6 |
13.7 |
|
NOP Interest Expense |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
NOP Allow Doubt Acc. |
- |
- |
- |
- |
0.0 |
|
NOP Inventory Loss |
- |
- |
0.0 |
-18.5 |
-19.0 |
|
NOP Exchange Loss |
- |
0.0 |
-11.0 |
0.0 |
0.0 |
|
NOP Other Expenses |
-3.7 |
-4.9 |
-4.0 |
-4.6 |
-5.0 |
|
Net Income Before Taxes |
716.9 |
748.3 |
955.1 |
610.4 |
564.1 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
261.7 |
263.1 |
333.1 |
215.4 |
208.4 |
|
Net Income After Taxes |
455.2 |
485.2 |
622.1 |
394.9 |
355.7 |
|
|
|
|
|
|
|
|
Minority Interest |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
-15.5 |
|
Net Income Before Extra. Items |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
Net Income |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
|
|
|
|
|
|
|
Earning Adjustment |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Com Excl ExtraOrd |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
544.2 |
544.2 |
544.5 |
544.8 |
547.0 |
|
Basic EPS Excluding ExtraOrdinary Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Basic EPS Including ExtraOrdinary Item |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
442.1 |
472.0 |
604.9 |
379.8 |
340.2 |
|
Diluted Weighted Average Shares |
544.4 |
544.3 |
544.6 |
545.0 |
547.6 |
|
Diluted EPS Excluding ExtraOrd Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Diluted EPS Including ExtraOrd Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
DPS-Common Stock |
0.50 |
0.46 |
0.43 |
0.33 |
0.25 |
|
Gross Dividends - Common Stock |
273.1 |
247.9 |
232.6 |
179.1 |
138.8 |
|
Normalized Income Before Taxes |
808.9 |
777.9 |
889.6 |
588.8 |
593.4 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
295.3 |
273.5 |
310.2 |
207.8 |
219.2 |
|
Normalized Income After Taxes |
513.7 |
504.4 |
579.4 |
381.0 |
374.2 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
500.5 |
491.2 |
562.2 |
365.8 |
358.7 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.66 |
|
Diluted Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.65 |
|
Sales promotion expenses |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Research&Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Interest Expense |
0.1 |
0.0 |
0.2 |
1.3 |
1.5 |
|
Depreciation |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Reported Operating Profit |
783.3 |
754.5 |
882.4 |
498.7 |
566.4 |
|
Reported Ordinary Profit |
797.8 |
741.4 |
965.6 |
553.8 |
574.8 |
|
Service Cost |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Interest Cost |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Expected Return on Plan Assets |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Actuarial Gains and Losses |
7.3 |
10.2 |
12.2 |
-1.3 |
-4.6 |
|
Prior Service Cost |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
-6.4 |
|
Pension Exp. due to Acct. Changes |
- |
- |
- |
1.0 |
- |
|
Additional Retire. Benefits, Nonrecurr. |
0.3 |
- |
0.6 |
- |
5.6 |
|
Domestic Pension Plan Expense |
37.4 |
38.0 |
36.5 |
19.0 |
16.3 |
|
Defined Contribution Expense |
10.6 |
9.5 |
8.6 |
7.3 |
6.3 |
|
Total Pension Expense |
48.0 |
47.5 |
45.1 |
26.3 |
22.6 |
|
Discount Rate |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
|
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
76.94 |
81.105 |
93.095 |
90.65 |
111.715 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Cash & Deposit |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
654.9 |
|
Acc.& Note Rcvbl. |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
957.9 |
|
Marketable Secs. |
792.8 |
736.1 |
560.3 |
603.6 |
586.7 |
|
Inventories |
- |
- |
- |
- |
494.0 |
|
Inventories - merchandise&finished goods |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
- |
|
Inventories - work-in-process |
0.3 |
0.2 |
0.1 |
0.6 |
- |
|
Inventories - raw materials&supplies |
230.3 |
190.1 |
224.8 |
187.4 |
- |
|
Deferred Inc. Tax |
295.6 |
245.7 |
226.2 |
240.9 |
183.2 |
|
Other Cur. Asset |
164.2 |
153.2 |
181.5 |
109.2 |
75.9 |
|
Allow Doubt. Acc. |
0.0 |
-0.1 |
-0.4 |
-0.7 |
-0.5 |
|
Total Current Assets |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
2,952.2 |
|
|
|
|
|
|
|
|
Buildings & Structures |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
969.2 |
|
Depreciation - Buildings & Structures |
-938.0 |
-932.0 |
-759.8 |
-746.1 |
-562.2 |
|
Machinery, Equip. & Vehicles |
1,099.8 |
1,075.1 |
899.6 |
835.5 |
613.4 |
|
Depreciation - Machi., Equip. & Vehicles |
-892.8 |
-838.5 |
-662.9 |
-602.6 |
-446.8 |
|
Tools, Furniture & Fixtures |
543.6 |
497.0 |
406.8 |
389.4 |
301.8 |
|
Depreciation - Tools, Furniture & Fix. |
-462.5 |
-416.4 |
-334.1 |
-317.9 |
-243.6 |
|
Land |
132.3 |
122.0 |
106.3 |
109.6 |
88.9 |
|
Constr. In Progr. |
35.3 |
24.8 |
16.4 |
60.5 |
107.3 |
|
Other, prop., plants, & equip., gross |
0.8 |
0.6 |
0.2 |
0.0 |
- |
|
Accum. depr - other PPE |
-0.3 |
-0.2 |
0.0 |
0.0 |
- |
|
Software |
4.3 |
7.9 |
11.3 |
27.2 |
23.7 |
|
Other Intangible |
21.2 |
21.2 |
23.5 |
7.0 |
9.6 |
|
Investment Secs. |
82.8 |
92.8 |
103.7 |
158.7 |
150.7 |
|
Investment Secs.-stock |
0.8 |
0.7 |
- |
- |
- |
|
LT Loans |
0.1 |
0.2 |
0.3 |
0.5 |
0.6 |
|
Deferred Income Tax |
182.4 |
184.2 |
156.8 |
134.6 |
80.5 |
|
Other Assets |
115.1 |
108.5 |
88.9 |
69.6 |
65.1 |
|
Allow Doubt Acc. |
-2.2 |
-2.3 |
-2.4 |
-2.5 |
-2.2 |
|
Translatn. Adjust |
- |
- |
- |
- |
0.0 |
|
Total Assets |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
4,108.1 |
|
|
|
|
|
|
|
|
Acc.& Note Payab. |
225.5 |
240.3 |
368.0 |
317.3 |
155.1 |
|
Cur. Corp. Bond |
- |
- |
- |
0.0 |
2.7 |
|
Cur.Convert. Bond |
- |
- |
- |
0.0 |
0.4 |
|
Current lease obligations |
- |
- |
0.1 |
0.0 |
- |
|
Other Payable |
102.5 |
73.2 |
70.9 |
77.8 |
46.6 |
|
Inc. Tax Payable |
184.0 |
45.4 |
237.8 |
125.5 |
146.1 |
|
Deferred Inc. Tax |
- |
- |
- |
0.0 |
0.0 |
|
Consumption taxes payable |
22.0 |
6.5 |
44.7 |
3.0 |
10.4 |
|
Accrued Expenses |
242.9 |
200.1 |
245.9 |
227.8 |
157.9 |
|
Allow for Bonus |
68.6 |
56.6 |
61.6 |
48.5 |
40.6 |
|
Allow for Director's Bonus |
2.4 |
2.7 |
1.9 |
2.3 |
1.8 |
|
Returned Goods |
- |
- |
- |
- |
0.0 |
|
Allowance for loss on disaster |
0.8 |
0.0 |
- |
- |
- |
|
Provision for environmental measures |
0.4 |
0.0 |
- |
- |
- |
|
Sales Discount & Other |
25.8 |
30.0 |
32.7 |
42.5 |
36.6 |
|
Other Cur. Liabs |
19.5 |
18.3 |
15.7 |
21.4 |
26.7 |
|
Total Current Liabilities |
894.4 |
672.9 |
1,079.3 |
866.2 |
624.7 |
|
|
|
|
|
|
|
|
Corp. Bond |
- |
- |
- |
- |
0.0 |
|
Convertible Bond |
- |
- |
- |
- |
0.0 |
|
Lease obligations |
- |
- |
0.1 |
0.0 |
- |
|
Total Long Term Debt |
- |
- |
0.1 |
0.0 |
0.0 |
|
|
|
|
|
|
|
|
Deferred tax liabilities |
1.4 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Accrued Retire. |
33.8 |
32.0 |
29.1 |
23.0 |
23.3 |
|
Provision for environmental measures |
2.3 |
0.0 |
- |
- |
- |
|
Director Benefit |
9.5 |
9.0 |
8.2 |
8.5 |
5.7 |
|
Other Liabs. |
25.7 |
8.8 |
20.4 |
0.8 |
0.9 |
|
Minority Inter. |
15.7 |
16.8 |
19.2 |
18.2 |
19.9 |
|
Total Liabilities |
982.7 |
739.5 |
1,156.3 |
916.7 |
674.6 |
|
|
|
|
|
|
|
|
Common Stock |
948.3 |
899.6 |
783.8 |
804.9 |
653.0 |
|
Paid-in Capital |
1,206.3 |
1,144.4 |
997.0 |
1,023.9 |
830.6 |
|
Retained Erngs. |
4,412.2 |
4,039.7 |
3,308.3 |
2,989.6 |
2,220.8 |
|
Treasury Stock |
-471.3 |
-447.0 |
-389.6 |
-388.0 |
-314.3 |
|
Unrealized Gains |
10.9 |
16.5 |
17.6 |
14.9 |
24.7 |
|
Translation Adj. |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
17.4 |
|
New Stock Subscription Right |
13.2 |
9.6 |
5.8 |
3.6 |
1.2 |
|
Total Equity |
5,950.9 |
5,524.1 |
4,650.0 |
4,362.0 |
3,433.5 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders' Equity |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.6 |
4,108.1 |
|
|
|
|
|
|
|
|
S/O-Common Stock |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
T/S-Common Stock |
15.5 |
15.5 |
15.5 |
14.9 |
14.8 |
|
Full-Time Employees |
6,779 |
6,709 |
6,485 |
6,383 |
6,257 |
|
Number of Common Shareholders |
49,522 |
50,418 |
55,513 |
44,372 |
45,416 |
|
LT debt maturing within yr |
- |
- |
- |
- |
3.1 |
|
Remaining |
2.0 |
1.8 |
1.6 |
- |
- |
|
Total Long Term Debt, Supplemental |
2.0 |
1.8 |
1.6 |
- |
3.1 |
|
Capital Lease maturing within 1 yr |
0.3 |
0.2 |
0.1 |
- |
- |
|
Capital Lease maturing within 2 yr |
0.2 |
0.1 |
0.0 |
- |
- |
|
Capital Lease maturing within 3 yr |
0.0 |
0.0 |
0.0 |
- |
- |
|
Capital Lease maturing within 4 yr |
0.0 |
0.0 |
0.0 |
- |
- |
|
Remaining |
0.0 |
0.0 |
0.0 |
- |
- |
|
Total Capital Leases |
0.5 |
0.4 |
0.2 |
- |
- |
|
Pension Obligation |
871.3 |
816.3 |
702.0 |
695.7 |
550.3 |
|
Fair Value of Plan Assets |
811.6 |
771.9 |
649.2 |
640.6 |
561.5 |
|
Funded Status |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Total Funded Status |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Discount Rate |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
Unrecognized Prior Service Cost |
-20.4 |
-18.1 |
-19.8 |
-25.6 |
-26.2 |
|
Unrecognized Actuarial Gains and Losses |
46.3 |
33.7 |
46.3 |
60.7 |
-5.8 |
|
Prepaid Pension Benefits |
0.0 |
3.1 |
2.8 |
3.0 |
2.5 |
|
Reserve for Accrued Retirement Benefits |
-33.8 |
-32.0 |
-29.1 |
-23.0 |
-23.3 |
|
Net Assets Recognized on Balance Sheet |
-7.9 |
-13.3 |
0.2 |
15.0 |
-52.8 |
|
|
|
Annual Cash
Flows |
|
Financials in:
USD (mil) |
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Income Bf. Tax |
716.8 |
748.2 |
955.1 |
610.3 |
564.1 |
|
Depreciation |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Impairment Loss |
1.8 |
0.5 |
0.3 |
7.2 |
0.3 |
|
Accrued Retire Bnft. |
3.1 |
-1.2 |
6.4 |
-4.9 |
-13.0 |
|
Int.& Dividend Inc. |
-6.3 |
-5.1 |
-8.0 |
-19.7 |
-12.3 |
|
Interest Expenses |
0.1 |
0.0 |
0.2 |
1.3 |
1.5 |
|
Loss Retire FixAsset |
8.3 |
2.4 |
2.3 |
3.4 |
2.8 |
|
Gain Sale Assets |
0.1 |
-0.2 |
-2.8 |
-4.0 |
0.3 |
|
G/L Sale/Value Inv.Secs. |
2.7 |
-1.0 |
0.1 |
0.2 |
0.2 |
|
Acc.& Note Rcvbl |
29.6 |
89.9 |
-138.5 |
-24.2 |
-10.7 |
|
Inventory |
-23.5 |
-144.8 |
-144.0 |
-247.2 |
52.4 |
|
Acc.& Note Payable |
-24.5 |
-167.2 |
57.1 |
118.9 |
-90.9 |
|
Sales Tax Payable |
24.2 |
-43.3 |
47.5 |
-19.7 |
9.6 |
|
Other |
29.4 |
-67.7 |
-24.5 |
41.0 |
47.9 |
|
Int.& Dividend Rcv'd |
6.3 |
4.9 |
7.9 |
15.3 |
11.6 |
|
Interest Paid |
-0.1 |
-0.1 |
-0.2 |
-1.3 |
-1.5 |
|
Tax Paid |
-148.2 |
-442.7 |
-257.2 |
-291.0 |
-176.2 |
|
Adjustment |
- |
-0.1 |
- |
- |
- |
|
Loss on disaster |
59.3 |
0.0 |
- |
- |
- |
|
Proceeds from insurance income |
37.2 |
0.0 |
- |
- |
- |
|
Payments for loss on disaster |
-42.4 |
0.0 |
- |
- |
- |
|
Cash from Operating Activities |
873.2 |
177.4 |
709.9 |
379.9 |
512.5 |
|
|
|
|
|
|
|
|
Time deposit made |
-281.0 |
-266.1 |
-249.9 |
-1.3 |
0.0 |
|
Time deposit matured |
248.0 |
256.4 |
120.0 |
0.0 |
- |
|
Purch.-Market. Secs. |
-1,505.5 |
-1,428.2 |
-1,262.0 |
-1,814.3 |
-1,917.8 |
|
Sale-Market. Secs. |
1,489.4 |
1,343.0 |
1,350.1 |
1,953.7 |
2,062.5 |
|
Purch.-Invest. Secs. |
-0.1 |
-0.1 |
-6.7 |
-38.7 |
-29.8 |
|
Sale-Invest. Secs. |
0.0 |
18.4 |
0.0 |
3.7 |
11.3 |
|
Capital Expenditures |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
-191.9 |
|
Sale-Fixed Assets |
0.2 |
1.0 |
3.5 |
4.1 |
1.6 |
|
ST Loans, Net |
- |
- |
- |
0.0 |
0.0 |
|
LT Loans, Net |
- |
- |
- |
0.3 |
0.1 |
|
Other |
0.1 |
0.1 |
0.2 |
- |
- |
|
Cash from Investing Activities |
-189.9 |
-230.0 |
-216.4 |
-136.6 |
-63.8 |
|
|
|
|
|
|
|
|
Redemption-Bonds |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Treasury Stock, Net |
0.0 |
-0.1 |
-12.0 |
-0.7 |
-233.7 |
|
Dividend Paid |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
-154.0 |
|
Dividend Paid-Minor |
-14.1 |
-14.5 |
-16.0 |
-16.0 |
-12.9 |
|
Others financing activities |
-0.3 |
-0.1 |
0.0 |
0.0 |
- |
|
Cash from Financing Activities |
-308.0 |
-262.6 |
-237.7 |
-177.6 |
-400.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
-7.2 |
-18.9 |
-1.4 |
-95.4 |
-2.5 |
|
Net Change in Cash |
368.0 |
-334.1 |
254.4 |
-29.7 |
45.8 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
817.4 |
1,076.2 |
754.7 |
713.0 |
580.2 |
|
Net Cash - Ending Balance |
1,185.4 |
742.0 |
1,009.2 |
683.3 |
626.0 |
|
Cash Interest Paid |
0.1 |
0.1 |
0.2 |
1.3 |
1.5 |
|
Cash Taxes Paid |
148.2 |
442.7 |
257.2 |
291.0 |
176.2 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Sales |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
Total Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
|
|
|
|
|
|
|
Cost of Revenue |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Cost of Revenue, Total |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Gross Profit |
2,710.3 |
2,472.9 |
2,521.9 |
1,933.4 |
1,762.1 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
554.9 |
485.6 |
478.2 |
441.9 |
336.7 |
|
Labor & Related Expense |
470.4 |
428.4 |
391.5 |
328.0 |
267.0 |
|
Advertising Expense |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Total Selling/General/Administrative Expenses |
1,226.1 |
1,095.2 |
1,048.6 |
919.9 |
714.7 |
|
Research & Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Depreciation |
- |
- |
- |
- |
20.3 |
|
Depreciation/Amortization |
- |
- |
- |
- |
20.3 |
|
Restructuring Charge |
0.9 |
-5.5 |
13.1 |
5.2 |
12.9 |
|
Impairment-Assets Held for Use |
10.7 |
3.9 |
2.3 |
3.4 |
2.8 |
|
Impairment-Assets Held for Sale |
3.2 |
31.5 |
-78.1 |
13.2 |
-3.1 |
|
Other Unusual Expense (Income) |
77.2 |
-0.1 |
0.0 |
-57.9 |
0.3 |
|
Unusual Expense (Income) |
91.9 |
29.8 |
-62.8 |
-36.1 |
12.8 |
|
Other, Net |
- |
- |
- |
- |
0.0 |
|
Other Operating Expenses, Total |
- |
- |
- |
- |
0.0 |
|
Total Operating Expense |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
2,374.3 |
|
|
|
|
|
|
|
|
Operating Income |
691.4 |
724.7 |
945.2 |
534.8 |
553.6 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
Interest Expense, Net Non-Operating |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
Interest Income -
Non-Operating |
4.8 |
3.6 |
6.9 |
15.6 |
11.4 |
|
Investment Income -
Non-Operating |
12.9 |
12.5 |
-9.8 |
67.8 |
8.4 |
|
Interest/Investment Income - Non-Operating |
17.7 |
16.2 |
-2.9 |
83.4 |
19.8 |
|
Interest Income (Expense) - Net Non-Operating Total |
17.6 |
16.1 |
-3.1 |
82.1 |
18.3 |
|
Gain (Loss) on Sale of Assets |
-0.1 |
0.2 |
2.8 |
-14.5 |
-16.5 |
|
Other Non-Operating Income (Expense) |
8.0 |
7.2 |
10.3 |
8.0 |
8.7 |
|
Other, Net |
8.0 |
7.2 |
10.3 |
8.0 |
8.7 |
|
Income Before Tax |
716.9 |
748.3 |
955.1 |
610.4 |
564.1 |
|
|
|
|
|
|
|
|
Total Income Tax |
261.7 |
263.1 |
333.1 |
215.4 |
208.4 |
|
Income After Tax |
455.2 |
485.2 |
622.1 |
394.9 |
355.7 |
|
|
|
|
|
|
|
|
Minority Interest |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
-15.5 |
|
Net Income Before Extraord Items |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
Net Income |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
|
|
|
|
|
|
|
Miscellaneous Earnings Adjustment |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Total Adjustments to Net Income |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Common Excl Extraord Items |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
544.2 |
544.2 |
544.5 |
544.8 |
547.0 |
|
Basic EPS Excl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Basic/Primary EPS Incl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
442.1 |
472.0 |
604.9 |
379.8 |
340.2 |
|
Diluted Weighted Average Shares |
544.4 |
544.3 |
544.6 |
545.0 |
547.6 |
|
Diluted EPS Excl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Diluted EPS Incl Extraord Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dividends per Share - Common Stock Primary Issue |
0.50 |
0.46 |
0.43 |
0.33 |
0.25 |
|
Gross Dividends - Common Stock |
273.1 |
247.9 |
232.6 |
179.1 |
138.8 |
|
Interest Expense, Supplemental |
0.1 |
0.0 |
0.2 |
1.3 |
1.5 |
|
Depreciation, Supplemental |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Total Special Items |
92.0 |
29.6 |
-65.6 |
-21.6 |
29.3 |
|
Normalized Income Before Tax |
808.9 |
777.9 |
889.6 |
588.8 |
593.4 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
33.6 |
10.4 |
-22.9 |
-7.6 |
10.8 |
|
Inc Tax Ex Impact of Sp Items |
295.3 |
273.5 |
310.2 |
207.8 |
219.2 |
|
Normalized Income After Tax |
513.7 |
504.4 |
579.4 |
381.0 |
374.2 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
500.5 |
491.2 |
562.2 |
365.8 |
358.7 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.66 |
|
Diluted Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.65 |
|
Advertising Expense, Supplemental |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Research & Development Exp, Supplemental |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Reported Operating Profit |
783.3 |
754.5 |
882.4 |
498.7 |
566.4 |
|
Reported Ordinary Profit |
797.8 |
741.4 |
965.6 |
553.8 |
574.8 |
|
Normalized EBIT |
783.4 |
754.5 |
882.5 |
498.7 |
566.4 |
|
Normalized EBITDA |
982.9 |
959.4 |
1,090.8 |
692.9 |
693.0 |
|
Interest Cost - Domestic |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Service Cost - Domestic |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Prior Service Cost - Domestic |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
-6.4 |
|
Expected Return on Assets - Domestic |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Actuarial Gains and Losses - Domestic |
7.3 |
10.2 |
12.2 |
-1.3 |
-4.6 |
|
Transition Costs - Domestic |
- |
- |
- |
1.0 |
- |
|
Other Pension, Net - Domestic |
0.3 |
- |
0.6 |
- |
5.6 |
|
Domestic Pension Plan Expense |
37.4 |
38.0 |
36.5 |
19.0 |
16.3 |
|
Defined Contribution Expense - Domestic |
10.6 |
9.5 |
8.6 |
7.3 |
6.3 |
|
Total Pension Expense |
48.0 |
47.5 |
45.1 |
26.3 |
22.6 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
Total Plan Interest Cost |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Total Plan Service Cost |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Total Plan Expected Return |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Total Plan Other Expense |
0.3 |
- |
0.6 |
- |
5.6 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Mar-2012 |
31-Dec-2011 |
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
|
Period Length |
3 Months |
3 Months |
3 Months |
3 Months |
3 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.208816 |
77.302742 |
77.752043 |
81.605269 |
82.241044 |
|
|
|
|
|
|
|
|
Net Sales |
1,139.5 |
1,261.3 |
1,210.0 |
1,179.0 |
1,042.3 |
|
Revenue |
1,139.5 |
1,261.3 |
1,210.0 |
1,179.0 |
1,042.3 |
|
Total Revenue |
1,139.5 |
1,261.3 |
1,210.0 |
1,179.0 |
1,042.3 |
|
|
|
|
|
|
|
|
Cost of Revenue |
500.1 |
545.2 |
525.0 |
483.2 |
426.9 |
|
Cost of Revenue, Total |
500.1 |
545.2 |
525.0 |
483.2 |
426.9 |
|
Gross Profit |
639.4 |
716.1 |
685.0 |
695.8 |
615.5 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
111.2 |
107.1 |
135.3 |
129.2 |
120.6 |
|
Labor & Related Expense |
118.6 |
183.8 |
123.5 |
116.0 |
111.5 |
|
Advertising Expense |
34.9 |
75.4 |
51.7 |
39.5 |
35.6 |
|
Total Selling/General/Administrative Expenses |
264.8 |
366.4 |
310.5 |
284.7 |
267.8 |
|
Research & Development |
164.8 |
189.1 |
183.8 |
170.5 |
158.4 |
|
Restructuring Charge |
- |
0.3 |
0.6 |
0.0 |
0.0 |
|
Impairment-Assets Held for Use |
0.4 |
7.8 |
4.7 |
0.2 |
0.3 |
|
Impairment-Assets Held for Sale |
-5.0 |
-20.6 |
22.3 |
14.4 |
-15.6 |
|
Other Unusual Expense (Income) |
-0.5 |
-34.8 |
17.4 |
6.0 |
86.2 |
|
Unusual Expense (Income) |
-5.1 |
-47.4 |
45.0 |
20.6 |
70.9 |
|
Total Operating Expense |
924.6 |
1,053.3 |
1,064.4 |
959.1 |
923.9 |
|
|
|
|
|
|
|
|
Operating Income |
214.9 |
207.9 |
145.6 |
219.9 |
118.4 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Interest Expense, Net Non-Operating |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Interest Income -
Non-Operating |
1.5 |
1.3 |
1.4 |
1.0 |
1.0 |
|
Investment Income -
Non-Operating |
-12.9 |
-16.4 |
24.3 |
10.3 |
-6.7 |
|
Interest/Investment Income - Non-Operating |
-11.4 |
-15.0 |
25.7 |
11.3 |
-5.7 |
|
Interest Income (Expense) - Net Non-Operating Total |
-11.4 |
-15.1 |
25.7 |
11.3 |
-5.7 |
|
Gain (Loss) on Sale of Assets |
0.0 |
0.0 |
0.0 |
- |
0.0 |
|
Other Non-Operating Income (Expense) |
2.9 |
3.3 |
0.8 |
1.5 |
4.0 |
|
Other, Net |
2.9 |
3.3 |
0.8 |
1.5 |
4.0 |
|
Income Before Tax |
206.4 |
196.1 |
172.1 |
232.8 |
116.7 |
|
|
|
|
|
|
|
|
Total Income Tax |
85.8 |
87.9 |
40.0 |
80.2 |
53.5 |
|
Income After Tax |
120.5 |
108.2 |
132.1 |
152.5 |
63.2 |
|
|
|
|
|
|
|
|
Minority Interest |
-2.5 |
-3.5 |
-2.8 |
-4.2 |
-2.5 |
|
Net Income Before Extraord Items |
118.0 |
104.7 |
129.2 |
148.3 |
60.7 |
|
Net Income |
118.0 |
104.7 |
129.2 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Miscellaneous Earnings Adjustment |
0.0 |
0.1 |
-0.1 |
0.0 |
0.0 |
|
Total Adjustments to Net Income |
0.0 |
0.1 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Common Excl Extraord Items |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
544.2 |
544.2 |
544.2 |
544.2 |
544.2 |
|
Basic EPS Excl Extraord Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Basic/Primary EPS Incl Extraord Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
Diluted Weighted Average Shares |
544.4 |
544.6 |
544.2 |
544.3 |
544.3 |
|
Diluted EPS Excl Extraord Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Diluted EPS Incl Extraord Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Dividends per Share - Common Stock Primary Issue |
0.00 |
0.26 |
0.00 |
0.25 |
0.00 |
|
Gross Dividends - Common Stock |
0.0 |
140.8 |
0.0 |
133.4 |
0.0 |
|
Interest Expense, Supplemental |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Depreciation, Supplemental |
43.9 |
58.4 |
53.4 |
41.6 |
46.6 |
|
Total Special Items |
-5.1 |
-47.4 |
45.0 |
20.6 |
70.9 |
|
Normalized Income Before Tax |
201.2 |
148.8 |
217.1 |
253.4 |
187.6 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
-2.1 |
-21.2 |
10.5 |
7.1 |
32.5 |
|
Inc Tax Ex Impact of Sp Items |
83.7 |
66.7 |
50.5 |
87.3 |
86.0 |
|
Normalized Income After Tax |
117.5 |
82.1 |
166.6 |
166.0 |
101.6 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
115.0 |
78.7 |
163.7 |
161.7 |
99.0 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.21 |
0.14 |
0.30 |
0.30 |
0.18 |
|
Diluted Normalized EPS |
0.21 |
0.14 |
0.30 |
0.30 |
0.18 |
|
Advertising Expense, Supplemental |
34.9 |
75.4 |
51.7 |
39.5 |
35.6 |
|
Research & Development Exp, Supplemental |
164.8 |
189.1 |
183.8 |
170.5 |
158.4 |
|
Reported Operating Profit |
209.8 |
160.6 |
190.6 |
240.5 |
189.2 |
|
Reported Ordinary Profit |
205.8 |
162.0 |
191.3 |
238.9 |
202.9 |
|
Normalized EBIT |
209.8 |
160.6 |
190.7 |
240.5 |
189.3 |
|
Normalized EBITDA |
253.7 |
219.0 |
244.1 |
282.2 |
235.9 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per share
items (actual units) |
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
76.94 |
81.105 |
93.095 |
90.65 |
111.715 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Cash & Equivalents |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
654.9 |
|
Short Term Investments |
792.8 |
736.1 |
560.3 |
603.6 |
586.7 |
|
Cash and Short Term Investments |
2,185.6 |
1,675.7 |
1,709.4 |
1,384.3 |
1,241.7 |
|
Accounts Receivable -
Trade, Gross |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
957.9 |
|
Provision for Doubtful
Accounts |
0.0 |
-0.1 |
-0.4 |
-0.7 |
-0.5 |
|
Trade Accounts Receivable - Net |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
957.4 |
|
Total Receivables, Net |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
957.4 |
|
Inventories - Finished Goods |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
- |
|
Inventories - Work In Progress |
0.3 |
0.2 |
0.1 |
0.6 |
- |
|
Inventories - Raw Materials |
230.3 |
190.1 |
224.8 |
187.4 |
- |
|
Total Inventory |
1,364.5 |
1,293.2 |
995.1 |
868.6 |
494.0 |
|
Deferred Income Tax - Current Asset |
295.6 |
245.7 |
226.2 |
240.9 |
183.2 |
|
Other Current Assets |
164.2 |
153.2 |
181.5 |
109.2 |
75.9 |
|
Other Current Assets, Total |
459.8 |
398.9 |
407.7 |
350.1 |
259.1 |
|
Total Current Assets |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
2,952.2 |
|
|
|
|
|
|
|
|
Buildings |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
969.2 |
|
Land/Improvements |
132.3 |
122.0 |
106.3 |
109.6 |
88.9 |
|
Machinery/Equipment |
1,643.3 |
1,572.2 |
1,306.4 |
1,224.9 |
915.2 |
|
Construction in
Progress |
35.3 |
24.8 |
16.4 |
60.5 |
107.3 |
|
Other
Property/Plant/Equipment |
0.8 |
0.6 |
0.2 |
0.0 |
- |
|
Property/Plant/Equipment - Gross |
3,371.5 |
3,271.5 |
2,763.0 |
2,751.5 |
2,080.6 |
|
Accumulated Depreciation |
-2,293.6 |
-2,187.0 |
-1,756.9 |
-1,666.7 |
-1,252.6 |
|
Property/Plant/Equipment - Net |
1,077.9 |
1,084.4 |
1,006.1 |
1,084.9 |
828.0 |
|
Intangibles, Net |
25.5 |
29.1 |
34.8 |
34.3 |
33.3 |
|
LT Investment - Affiliate Companies |
0.8 |
0.7 |
- |
- |
- |
|
LT Investments - Other |
82.8 |
92.8 |
103.7 |
158.7 |
150.7 |
|
Long Term Investments |
83.6 |
93.5 |
103.7 |
158.7 |
150.7 |
|
Note Receivable - Long Term |
0.1 |
0.2 |
0.3 |
0.5 |
0.6 |
|
Deferred Income Tax - Long Term Asset |
182.4 |
184.2 |
156.8 |
134.6 |
80.5 |
|
Other Long Term Assets |
112.9 |
106.2 |
86.5 |
67.1 |
62.9 |
|
Other Long Term Assets, Total |
295.2 |
290.4 |
243.3 |
201.6 |
143.3 |
|
Total Assets |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
4,108.1 |
|
|
|
|
|
|
|
|
Accounts Payable |
225.5 |
240.3 |
368.0 |
317.3 |
155.1 |
|
Accrued Expenses |
335.9 |
265.8 |
354.1 |
281.6 |
210.6 |
|
Notes Payable/Short Term Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Current Portion - Long Term Debt/Capital Leases |
- |
- |
0.1 |
0.0 |
3.1 |
|
Income Taxes Payable |
184.0 |
45.4 |
237.8 |
125.5 |
146.1 |
|
Other Payables |
102.5 |
73.2 |
70.9 |
77.8 |
46.6 |
|
Deferred Income Tax - Current Liability |
- |
- |
- |
0.0 |
0.0 |
|
Other Current Liabilities |
46.6 |
48.4 |
48.4 |
63.9 |
63.3 |
|
Other Current liabilities, Total |
333.1 |
166.9 |
357.1 |
267.3 |
256.0 |
|
Total Current Liabilities |
894.4 |
672.9 |
1,079.3 |
866.2 |
624.7 |
|
|
|
|
|
|
|
|
Long Term Debt |
- |
- |
- |
- |
0.0 |
|
Capital Lease Obligations |
- |
- |
0.1 |
0.0 |
- |
|
Total Long Term Debt |
0.0 |
0.0 |
0.1 |
0.0 |
0.0 |
|
Total Debt |
0.0 |
0.0 |
0.2 |
0.0 |
3.1 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
1.4 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Deferred Income Tax |
1.4 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Minority Interest |
15.7 |
16.8 |
19.2 |
18.2 |
19.9 |
|
Reserves |
2.3 |
0.0 |
- |
- |
- |
|
Pension Benefits - Underfunded |
43.2 |
41.0 |
37.3 |
31.5 |
29.0 |
|
Other Long Term Liabilities |
25.7 |
8.8 |
20.4 |
0.8 |
0.9 |
|
Other Liabilities, Total |
71.3 |
49.8 |
57.7 |
32.3 |
29.9 |
|
Total Liabilities |
982.7 |
739.5 |
1,156.3 |
916.7 |
674.6 |
|
|
|
|
|
|
|
|
Common Stock |
948.3 |
899.6 |
783.8 |
804.9 |
653.0 |
|
Common Stock |
948.3 |
899.6 |
783.8 |
804.9 |
653.0 |
|
Additional Paid-In Capital |
1,219.5 |
1,153.9 |
1,002.7 |
1,027.5 |
831.9 |
|
Retained Earnings (Accumulated Deficit) |
4,412.2 |
4,039.7 |
3,308.3 |
2,989.6 |
2,220.8 |
|
Treasury Stock - Common |
-471.3 |
-447.0 |
-389.6 |
-388.0 |
-314.3 |
|
Unrealized Gain (Loss) |
10.9 |
16.5 |
17.6 |
14.9 |
24.7 |
|
Translation Adjustment |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
17.4 |
|
Other Equity, Total |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
17.4 |
|
Total Equity |
5,950.9 |
5,524.1 |
4,650.0 |
4,362.0 |
3,433.5 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.6 |
4,108.1 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.8 |
544.8 |
|
Treasury Shares - Common Stock Primary Issue |
15.5 |
15.5 |
15.5 |
14.9 |
14.8 |
|
Employees |
6,779 |
6,709 |
6,485 |
6,383 |
6,257 |
|
Number of Common Shareholders |
49,522 |
50,418 |
55,513 |
44,372 |
45,416 |
|
Total Long Term Debt, Supplemental |
2.0 |
1.8 |
1.6 |
- |
3.1 |
|
Long Term Debt Maturing within 1 Year |
- |
- |
- |
- |
3.1 |
|
Long Term Debt Matur. in Year 6 & Beyond |
2.0 |
1.8 |
1.6 |
- |
0.0 |
|
Total Capital Leases, Supplemental |
0.5 |
0.4 |
0.2 |
- |
- |
|
Capital Lease Payments Due in Year 1 |
0.3 |
0.2 |
0.1 |
- |
- |
|
Capital Lease Payments Due in Year 2 |
0.2 |
0.1 |
0.0 |
- |
- |
|
Capital Lease Payments Due in Year 3 |
0.0 |
0.0 |
0.0 |
- |
- |
|
Capital Lease Payments Due in Year 4 |
0.0 |
0.0 |
0.0 |
- |
- |
|
Capital Lease Payments Due in 2-3 Years |
0.2 |
0.2 |
0.1 |
- |
- |
|
Capital Lease Payments Due in 4-5 Years |
0.0 |
0.0 |
0.0 |
- |
- |
|
Cap. Lease Pymts. Due in Year 6 & Beyond |
0.0 |
0.0 |
0.0 |
- |
- |
|
Pension Obligation - Domestic |
871.3 |
816.3 |
702.0 |
695.7 |
550.3 |
|
Plan Assets - Domestic |
811.6 |
771.9 |
649.2 |
640.6 |
561.5 |
|
Funded Status - Domestic |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Total Funded Status |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
11.2 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
Prepaid Benefits - Domestic |
0.0 |
3.1 |
2.8 |
3.0 |
2.5 |
|
Accrued Liabilities - Domestic |
-33.8 |
-32.0 |
-29.1 |
-23.0 |
-23.3 |
|
Other Assets, Net - Domestic |
25.9 |
15.6 |
26.5 |
35.0 |
-32.0 |
|
Net Assets Recognized on Balance Sheet |
-7.9 |
-13.3 |
0.2 |
15.0 |
-52.8 |
|
Total Plan Obligations |
871.3 |
816.3 |
702.0 |
695.7 |
550.3 |
|
Total Plan Assets |
811.6 |
771.9 |
649.2 |
640.6 |
561.5 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Mar-2012 |
31-Dec-2011 |
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
82.385362 |
76.94 |
77.08 |
80.76 |
82.88 |
|
|
|
|
|
|
|
|
Cash & Equivalents |
1,494.3 |
1,392.8 |
1,435.8 |
1,352.5 |
1,227.3 |
|
Short Term Investments |
813.2 |
792.8 |
765.4 |
730.5 |
699.8 |
|
Cash and Short Term Investments |
2,307.4 |
2,185.6 |
2,201.2 |
2,083.0 |
1,927.1 |
|
Accounts Receivable -
Trade, Gross |
1,148.7 |
1,441.6 |
1,277.2 |
1,310.6 |
1,141.4 |
|
Provision for Doubtful
Accounts |
0.0 |
0.0 |
-0.1 |
-0.1 |
-0.1 |
|
Trade Accounts Receivable - Net |
1,148.6 |
1,441.5 |
1,277.1 |
1,310.6 |
1,141.3 |
|
Total Receivables, Net |
1,148.6 |
1,441.5 |
1,277.1 |
1,310.6 |
1,141.3 |
|
Inventories - Finished Goods |
1,020.1 |
1,133.9 |
1,171.7 |
1,044.7 |
1,034.9 |
|
Inventories - Work In Progress |
2.1 |
0.3 |
4.8 |
2.4 |
6.2 |
|
Inventories - Raw Materials |
206.7 |
230.3 |
325.0 |
320.3 |
268.1 |
|
Total Inventory |
1,228.9 |
1,364.5 |
1,501.5 |
1,367.5 |
1,309.3 |
|
Deferred Income Tax - Current Asset |
266.8 |
295.6 |
286.1 |
229.0 |
279.1 |
|
Other Current Assets |
159.3 |
164.2 |
153.4 |
112.8 |
199.7 |
|
Other Current Assets, Total |
426.1 |
459.8 |
439.5 |
341.7 |
478.7 |
|
Total Current Assets |
5,111.2 |
5,451.4 |
5,419.3 |
5,102.8 |
4,856.4 |
|
|
|
|
|
|
|
|
Property/Plant/Equipment - Net |
982.6 |
1,077.9 |
1,060.9 |
1,034.3 |
1,039.1 |
|
Intangibles, Net |
23.2 |
25.5 |
27.7 |
29.4 |
28.2 |
|
LT Investments - Other |
79.5 |
83.6 |
89.8 |
85.6 |
84.7 |
|
Long Term Investments |
79.5 |
83.6 |
89.8 |
85.6 |
84.7 |
|
Deferred Income Tax - Long Term Asset |
159.2 |
182.4 |
213.0 |
188.5 |
164.8 |
|
Other Long Term Assets |
107.5 |
112.9 |
122.6 |
114.0 |
104.2 |
|
Other Long Term Assets, Total |
266.7 |
295.3 |
335.6 |
302.5 |
269.0 |
|
Total Assets |
6,463.2 |
6,933.7 |
6,933.3 |
6,554.6 |
6,277.3 |
|
|
|
|
|
|
|
|
Accounts Payable |
290.2 |
225.5 |
378.9 |
352.3 |
356.0 |
|
Accrued Expenses |
113.2 |
68.6 |
122.9 |
61.0 |
101.7 |
|
Notes Payable/Short Term Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Income Taxes Payable |
73.8 |
184.0 |
125.2 |
135.2 |
85.9 |
|
Other Current Liabilities |
326.4 |
416.4 |
376.2 |
303.2 |
324.5 |
|
Other Current liabilities, Total |
400.1 |
600.4 |
501.5 |
438.3 |
410.4 |
|
Total Current Liabilities |
803.6 |
894.4 |
1,003.2 |
851.7 |
868.1 |
|
|
|
|
|
|
|
|
Total Long Term Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Total Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
|
|
|
|
|
|
|
Minority Interest |
13.3 |
15.7 |
12.7 |
17.0 |
12.4 |
|
Other Long Term Liabilities |
66.9 |
72.6 |
70.6 |
65.8 |
64.0 |
|
Other Liabilities, Total |
66.9 |
72.6 |
70.6 |
65.8 |
64.0 |
|
Total Liabilities |
883.8 |
982.7 |
1,086.5 |
934.4 |
944.5 |
|
|
|
|
|
|
|
|
Common Stock |
885.7 |
948.3 |
946.6 |
903.5 |
880.4 |
|
Common Stock |
885.7 |
948.3 |
946.6 |
903.5 |
880.4 |
|
Additional Paid-In Capital |
1,139.7 |
1,219.5 |
1,216.5 |
1,160.2 |
1,130.1 |
|
Retained Earnings (Accumulated Deficit) |
4,103.1 |
4,412.2 |
4,299.1 |
4,113.6 |
3,862.4 |
|
Treasury Stock - Common |
-440.1 |
-471.3 |
-470.4 |
-449.0 |
-437.5 |
|
Unrealized Gain (Loss) |
23.1 |
10.9 |
13.9 |
11.7 |
12.1 |
|
Translation Adjustment |
-132.1 |
-168.9 |
-158.9 |
-119.8 |
-114.7 |
|
Other Equity, Total |
-132.1 |
-168.9 |
-158.9 |
-119.8 |
-114.7 |
|
Total Equity |
5,579.4 |
5,950.9 |
5,846.7 |
5,620.3 |
5,332.8 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
6,463.1 |
6,933.6 |
6,933.3 |
6,554.7 |
6,277.3 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
544.2 |
544.2 |
544.2 |
544.2 |
544.2 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.2 |
544.2 |
|
Treasury Shares - Common Stock Primary Issue |
15.5 |
15.5 |
15.5 |
15.5 |
15.5 |
|
Employees |
- |
6,779 |
- |
6,818 |
6,635 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
716.8 |
748.2 |
955.1 |
610.3 |
564.1 |
|
Depreciation |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Depreciation/Depletion |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Unusual Items |
72.1 |
1.6 |
-0.1 |
6.9 |
3.5 |
|
Other Non-Cash Items |
-3.2 |
-6.3 |
-1.4 |
-23.3 |
-23.8 |
|
Non-Cash Items |
69.0 |
-4.7 |
-1.6 |
-16.4 |
-20.3 |
|
Accounts Receivable |
29.6 |
89.9 |
-138.5 |
-24.2 |
-10.7 |
|
Inventories |
-23.5 |
-144.8 |
-144.0 |
-247.2 |
52.4 |
|
Accounts Payable |
-24.5 |
-167.2 |
57.1 |
118.9 |
-90.9 |
|
Taxes Payable |
24.2 |
-43.3 |
47.5 |
-19.7 |
9.6 |
|
Other Operating Cash Flow |
-117.9 |
-505.6 |
-274.0 |
-236.0 |
-118.3 |
|
Changes in Working Capital |
-112.1 |
-771.0 |
-452.0 |
-408.3 |
-157.9 |
|
Cash from Operating Activities |
873.2 |
177.4 |
709.9 |
379.9 |
512.5 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
-191.9 |
|
Capital Expenditures |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
-191.9 |
|
Sale of Fixed Assets |
0.2 |
1.0 |
3.5 |
4.1 |
1.6 |
|
Sale/Maturity of Investment |
1,737.4 |
1,617.8 |
1,470.1 |
1,957.3 |
2,073.9 |
|
Purchase of Investments |
-1,786.6 |
-1,694.4 |
-1,518.7 |
-1,854.4 |
-1,947.5 |
|
Other Investing Cash Flow |
0.1 |
0.1 |
0.2 |
0.3 |
0.1 |
|
Other Investing Cash Flow Items, Total |
-48.9 |
-75.5 |
-44.8 |
107.4 |
128.1 |
|
Cash from Investing Activities |
-189.9 |
-230.0 |
-216.4 |
-136.6 |
-63.8 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
-12.9 |
|
Financing Cash Flow Items |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
-12.9 |
|
Cash Dividends Paid - Common |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
-154.0 |
|
Total Cash Dividends Paid |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
-154.0 |
|
Common Stock, Net |
0.0 |
-0.1 |
-12.0 |
-0.7 |
-233.7 |
|
Issuance (Retirement) of Stock, Net |
0.0 |
-0.1 |
-12.0 |
-0.7 |
-233.7 |
|
Long Term Debt
Reduction |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Long Term Debt, Net |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Issuance (Retirement) of Debt, Net |
- |
- |
0.0 |
-2.9 |
0.0 |
|
Cash from Financing Activities |
-308.0 |
-262.6 |
-237.7 |
-177.6 |
-400.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
-7.2 |
-18.9 |
-1.4 |
-95.4 |
-2.5 |
|
Net Change in Cash |
368.0 |
-334.1 |
254.4 |
-29.7 |
45.8 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
817.4 |
1,076.2 |
754.7 |
713.0 |
580.2 |
|
Net Cash - Ending Balance |
1,185.4 |
742.0 |
1,009.2 |
683.3 |
626.0 |
|
Cash Interest Paid |
0.1 |
0.1 |
0.2 |
1.3 |
1.5 |
|
Cash Taxes Paid |
148.2 |
442.7 |
257.2 |
291.0 |
176.2 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
31-Dec-2010 |
|
Period Length |
12 Months |
9 Months |
6 Months |
3 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
80.506255 |
81.907322 |
82.241044 |
87.789317 |
|
|
|
|
|
|
|
|
Net Income/Starting Line |
716.8 |
521.2 |
349.0 |
116.7 |
748.2 |
|
Depreciation |
199.5 |
141.4 |
88.3 |
46.6 |
204.8 |
|
Depreciation/Depletion |
199.5 |
141.4 |
88.3 |
46.6 |
204.8 |
|
Unusual Items |
72.1 |
98.7 |
81.4 |
74.0 |
1.6 |
|
Other Non-Cash Items |
-3.2 |
-4.1 |
-2.8 |
-1.1 |
-6.3 |
|
Non-Cash Items |
69.0 |
94.6 |
78.6 |
72.9 |
-4.7 |
|
Accounts Receivable |
29.6 |
184.7 |
93.6 |
229.9 |
89.9 |
|
Inventories |
-23.5 |
-152.9 |
-78.9 |
-42.2 |
-144.8 |
|
Accounts Payable |
-24.5 |
122.1 |
109.3 |
121.3 |
-167.2 |
|
Taxes Payable |
24.2 |
- |
- |
- |
-43.3 |
|
Other Operating Cash Flow |
-117.9 |
-68.5 |
-26.7 |
-63.6 |
-505.6 |
|
Changes in Working Capital |
-112.1 |
85.5 |
97.4 |
245.5 |
-771.0 |
|
Cash from Operating Activities |
873.2 |
842.7 |
613.3 |
481.7 |
177.4 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-141.0 |
-110.1 |
-74.6 |
-50.4 |
-154.5 |
|
Capital Expenditures |
-141.0 |
-110.1 |
-74.6 |
-50.4 |
-154.5 |
|
Sale of Fixed Assets |
0.2 |
0.1 |
0.0 |
0.0 |
1.0 |
|
Sale/Maturity of Investment |
1,737.4 |
1,192.4 |
861.2 |
352.7 |
1,617.8 |
|
Purchase of Investments |
-1,786.6 |
-1,161.6 |
-831.4 |
-311.5 |
-1,694.4 |
|
Other Investing Cash Flow |
0.1 |
-0.2 |
-0.3 |
-0.2 |
0.1 |
|
Other Investing Cash Flow Items, Total |
-48.9 |
30.7 |
29.5 |
41.0 |
-75.5 |
|
Cash from Investing Activities |
-189.9 |
-79.3 |
-45.0 |
-9.4 |
-230.0 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-14.4 |
-14.2 |
-7.9 |
-7.7 |
-14.6 |
|
Financing Cash Flow Items |
-14.4 |
-14.2 |
-7.9 |
-7.7 |
-14.6 |
|
Cash Dividends Paid - Common |
-293.6 |
-287.3 |
-152.7 |
-152.3 |
-247.9 |
|
Total Cash Dividends Paid |
-293.6 |
-287.3 |
-152.7 |
-152.3 |
-247.9 |
|
Common Stock, Net |
0.0 |
0.0 |
0.0 |
0.0 |
-0.1 |
|
Issuance (Retirement) of Stock, Net |
0.0 |
0.0 |
0.0 |
0.0 |
-0.1 |
|
Cash from Financing Activities |
-308.0 |
-301.5 |
-160.6 |
-160.0 |
-262.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
-7.2 |
-8.2 |
7.6 |
9.0 |
-18.9 |
|
Net Change in Cash |
368.0 |
453.7 |
415.2 |
321.2 |
-334.1 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
817.4 |
809.2 |
795.3 |
792.1 |
1,076.2 |
|
Net Cash - Ending Balance |
1,185.4 |
1,262.8 |
1,210.5 |
1,113.3 |
742.0 |
|
Cash Interest Paid |
0.1 |
0.0 |
0.0 |
0.0 |
0.1 |
|
Cash Taxes Paid |
148.2 |
150.1 |
36.0 |
31.4 |
442.7 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
117.767199 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Net Sales |
4,562.5 |
4,278.0 |
4,476.7 |
3,112.7 |
2,827.1 |
|
Other operating revenue |
124.2 |
45.0 |
105.1 |
- |
- |
|
Revenue on Patent |
- |
- |
- |
49.3 |
100.7 |
|
Total Revenue |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
2,927.9 |
|
|
|
|
|
|
|
|
Cost of Sales |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
1,165.8 |
|
Rsv-Return Good Adj |
- |
- |
- |
- |
0.0 |
|
Sales promotion expenses |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Payrolls & Bonuses |
399.6 |
366.7 |
325.6 |
286.2 |
231.5 |
|
Depreciaiton |
- |
- |
- |
- |
20.3 |
|
Provision for bonuses |
40.8 |
31.0 |
36.6 |
25.7 |
22.9 |
|
Provision for directors' bonuses |
- |
- |
- |
- |
1.7 |
|
Periodic retirement benefit costs |
30.0 |
30.8 |
29.4 |
16.2 |
10.2 |
|
Reserve for directors retire. benefits |
- |
- |
- |
- |
0.8 |
|
Research&Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Other general expenses |
554.9 |
485.6 |
478.2 |
441.9 |
336.7 |
|
SP Co-Development Settlement |
- |
- |
0.0 |
-61.3 |
0.0 |
|
SP Subsidy Income |
0.0 |
-0.6 |
0.0 |
-4.8 |
0.0 |
|
SP Sales Right License |
- |
- |
- |
- |
0.0 |
|
SP Restructuring Liquidate Gain |
0.0 |
-5.5 |
0.0 |
- |
0.0 |
|
SP G Extinguishment of tie-in stocks |
- |
0.0 |
-0.3 |
0.0 |
- |
|
SP Impairment Loss |
1.8 |
0.5 |
0.3 |
7.2 |
0.3 |
|
SP Restructuring expenses |
0.9 |
0.0 |
13.1 |
5.2 |
12.9 |
|
SP Periodic retirement benefit costs |
- |
- |
0.0 |
1.0 |
0.0 |
|
SP Provision for environmental measures |
3.5 |
0.0 |
- |
- |
- |
|
SP L on Adjust. for Chan. of Acct. Asset |
12.6 |
0.0 |
- |
- |
- |
|
SP Loss on disaster |
59.3 |
0.0 |
- |
- |
- |
|
SP L on valuation of golf club membershi |
0.1 |
0.0 |
- |
- |
- |
|
SP Loss Val Inv.Sec |
2.7 |
0.0 |
0.1 |
0.2 |
0.0 |
|
NOP G on valuation of derivatives |
- |
0.0 |
-78.3 |
0.0 |
-3.1 |
|
NOP Loss Retire FixAsset |
8.3 |
2.4 |
2.3 |
3.4 |
2.8 |
|
NOP L on valuation of derivatives |
0.4 |
31.5 |
0.0 |
13.0 |
0.0 |
|
NOP L on abandonment of fixed assets |
2.4 |
1.5 |
- |
- |
- |
|
Total Operating Expense |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
2,374.3 |
|
|
|
|
|
|
|
|
SP Gain Sale Assets |
0.0 |
0.2 |
2.8 |
4.1 |
0.0 |
|
SP Gain Sale Inv.Secs. |
0.0 |
1.1 |
0.0 |
- |
0.0 |
|
SP Gain Settlement of Affiliates |
- |
- |
- |
0.0 |
2.5 |
|
SP Loss Sale Fixed Assets |
-0.1 |
0.0 |
0.0 |
-0.1 |
0.0 |
|
SP Loss Sale Inv.Secs. |
0.0 |
0.0 |
0.0 |
- |
- |
|
NOP Interest Income |
4.8 |
3.6 |
6.9 |
15.6 |
11.4 |
|
NOP Dividend Income |
1.5 |
1.5 |
1.2 |
4.1 |
0.8 |
|
NOP Dividends income of life insurance |
4.3 |
0.0 |
0.0 |
3.2 |
2.7 |
|
NOP Exchange Gain |
7.1 |
10.0 |
0.0 |
60.5 |
4.9 |
|
NOP Patent Income |
- |
- |
- |
- |
0.0 |
|
NOP Other Income |
11.7 |
12.1 |
14.3 |
12.6 |
13.7 |
|
NOP Interest Expense |
-0.1 |
0.0 |
-0.2 |
-1.3 |
-1.5 |
|
NOP Allow Doubt Acc. |
- |
- |
- |
- |
0.0 |
|
NOP Inventory Loss |
- |
- |
0.0 |
-18.5 |
-19.0 |
|
NOP Exchange Loss |
- |
0.0 |
-11.0 |
0.0 |
0.0 |
|
NOP Other Expenses |
-3.7 |
-4.9 |
-4.0 |
-4.6 |
-5.0 |
|
Net Income Before Taxes |
716.9 |
748.3 |
955.1 |
610.4 |
564.1 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
261.7 |
263.1 |
333.1 |
215.4 |
208.4 |
|
Net Income After Taxes |
455.2 |
485.2 |
622.1 |
394.9 |
355.7 |
|
|
|
|
|
|
|
|
Minority Interest |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
-15.5 |
|
Net Income Before Extra. Items |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
Net Income |
442.2 |
472.0 |
605.0 |
379.8 |
340.2 |
|
|
|
|
|
|
|
|
Earning Adjustment |
-0.1 |
0.0 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Com Excl ExtraOrd |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
442.1 |
472.0 |
604.9 |
379.7 |
340.2 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
544.2 |
544.2 |
544.5 |
544.8 |
547.0 |
|
Basic EPS Excluding ExtraOrdinary Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Basic EPS Including ExtraOrdinary Item |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
442.1 |
472.0 |
604.9 |
379.8 |
340.2 |
|
Diluted Weighted Average Shares |
544.4 |
544.3 |
544.6 |
545.0 |
547.6 |
|
Diluted EPS Excluding ExtraOrd Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
Diluted EPS Including ExtraOrd Items |
0.81 |
0.87 |
1.11 |
0.70 |
0.62 |
|
DPS-Common Stock |
0.50 |
0.46 |
0.43 |
0.33 |
0.25 |
|
Gross Dividends - Common Stock |
273.1 |
247.9 |
232.6 |
179.1 |
138.8 |
|
Normalized Income Before Taxes |
808.9 |
777.9 |
889.6 |
588.8 |
593.4 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
295.3 |
273.5 |
310.2 |
207.8 |
219.2 |
|
Normalized Income After Taxes |
513.7 |
504.4 |
579.4 |
381.0 |
374.2 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
500.5 |
491.2 |
562.2 |
365.8 |
358.7 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.66 |
|
Diluted Normalized EPS |
0.92 |
0.90 |
1.03 |
0.67 |
0.65 |
|
Sales promotion expenses |
200.8 |
181.1 |
178.8 |
150.1 |
110.9 |
|
Research&Development |
700.8 |
623.1 |
590.8 |
514.8 |
460.6 |
|
Interest Expense |
0.1 |
0.0 |
0.2 |
1.3 |
1.5 |
|
Depreciation |
199.5 |
204.8 |
208.3 |
194.2 |
126.6 |
|
Reported Operating Profit |
783.3 |
754.5 |
882.4 |
498.7 |
566.4 |
|
Reported Ordinary Profit |
797.8 |
741.4 |
965.6 |
553.8 |
574.8 |
|
Service Cost |
33.7 |
30.6 |
27.5 |
25.1 |
22.0 |
|
Interest Cost |
18.5 |
16.6 |
15.0 |
13.3 |
11.4 |
|
Expected Return on Plan Assets |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
-11.7 |
|
Actuarial Gains and Losses |
7.3 |
10.2 |
12.2 |
-1.3 |
-4.6 |
|
Prior Service Cost |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
-6.4 |
|
Pension Exp. due to Acct. Changes |
- |
- |
- |
1.0 |
- |
|
Additional Retire. Benefits, Nonrecurr. |
0.3 |
- |
0.6 |
- |
5.6 |
|
Domestic Pension Plan Expense |
37.4 |
38.0 |
36.5 |
19.0 |
16.3 |
|
Defined Contribution Expense |
10.6 |
9.5 |
8.6 |
7.3 |
6.3 |
|
Total Pension Expense |
48.0 |
47.5 |
45.1 |
26.3 |
22.6 |
|
Discount Rate |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return |
1.30% |
0.60% |
0.80% |
0.70% |
0.70% |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
|
|
|
31-Mar-2012 |
31-Dec-2011 |
30-Sep-2011 |
30-Jun-2011 |
31-Mar-2011 |
|
Period Length |
3 Months |
3 Months |
3 Months |
3 Months |
3 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.208816 |
77.302742 |
77.752043 |
81.605269 |
82.241044 |
|
|
|
|
|
|
|
|
Net sales |
1,095.5 |
1,243.8 |
1,192.4 |
1,156.4 |
977.5 |
|
Other operating revenue |
43.9 |
17.4 |
17.6 |
22.6 |
64.9 |
|
Total Revenue |
1,139.5 |
1,261.3 |
1,210.0 |
1,179.0 |
1,042.3 |
|
|
|
|
|
|
|
|
Cost of Sales |
500.1 |
545.2 |
525.0 |
483.2 |
426.9 |
|
Sales Promotion |
34.9 |
75.4 |
51.7 |
39.5 |
35.6 |
|
Saraly/Bonus |
77.5 |
176.7 |
77.6 |
73.6 |
74.7 |
|
Allowance Bonus |
33.2 |
- |
37.6 |
35.2 |
29.5 |
|
Research&Development |
164.8 |
189.1 |
183.8 |
170.5 |
158.4 |
|
Periodic Retirement Benefit Costs |
8.0 |
7.2 |
8.3 |
7.2 |
7.3 |
|
Other SGA |
111.2 |
107.1 |
135.3 |
129.2 |
120.6 |
|
SP Subsidy Income |
-0.5 |
0.0 |
- |
0.0 |
0.0 |
|
SP Other Gains |
- |
-34.8 |
- |
- |
- |
|
SP Impairment Loss |
0.0 |
0.4 |
1.3 |
0.2 |
0.0 |
|
SP Loss on Disaster |
0.0 |
- |
11.2 |
5.7 |
73.8 |
|
SP Loss on Business Reorganization |
- |
0.3 |
0.6 |
0.0 |
0.0 |
|
SP Loss Val Inv.Sec |
- |
0.0 |
- |
- |
0.0 |
|
SP L on Adjust. for Chan. of Acct. Asset |
0.0 |
- |
- |
- |
12.4 |
|
SP Other Special Loss |
- |
- |
6.2 |
0.3 |
0.0 |
|
NOP G on valuation of derivatives |
-5.0 |
-20.6 |
0.0 |
- |
-15.6 |
|
NOP Loss Retire Fixed Assets |
0.2 |
7.0 |
1.5 |
- |
0.2 |
|
NOP Loss on Valuation of Derivatives |
- |
- |
22.3 |
14.4 |
0.0 |
|
NOP L on abandonment of fixed assets |
0.2 |
0.5 |
1.9 |
- |
0.1 |
|
Total Operating Expense |
924.6 |
1,053.3 |
1,064.4 |
959.1 |
923.9 |
|
|
|
|
|
|
|
|
NOP Interest Income |
1.5 |
1.3 |
1.4 |
1.0 |
1.0 |
|
NOP Exchange Gain |
- |
- |
24.3 |
10.3 |
0.0 |
|
NOP Insurance Dividend |
4.3 |
- |
- |
- |
4.1 |
|
NOP Other Income |
3.6 |
3.3 |
1.3 |
3.7 |
5.2 |
|
NOP Interest Expense |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
NOP Exchange Loss |
-17.2 |
-16.4 |
0.0 |
- |
-10.9 |
|
NOP Other Expenses |
-0.7 |
- |
-0.5 |
-2.2 |
-1.2 |
|
SP Gain Sale Assets |
0.0 |
0.0 |
0.0 |
- |
0.0 |
|
SP Gain Sale Inv.Secs. |
- |
0.0 |
0.0 |
- |
- |
|
SP Loss Sale Fixed Asset |
0.0 |
- |
- |
- |
0.0 |
|
Net Income Before Taxes |
206.4 |
196.1 |
172.1 |
232.8 |
116.7 |
|
|
|
|
|
|
|
|
Provision for Income Taxes |
85.8 |
87.9 |
40.0 |
80.2 |
53.5 |
|
Net Income After Taxes |
120.5 |
108.2 |
132.1 |
152.5 |
63.2 |
|
|
|
|
|
|
|
|
Minority Interest |
-2.5 |
-3.5 |
-2.8 |
-4.2 |
-2.5 |
|
Net Income Before Extra. Items |
118.0 |
104.7 |
129.2 |
148.3 |
60.7 |
|
Net Income |
118.0 |
104.7 |
129.2 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Earning Adjustment |
0.0 |
0.1 |
-0.1 |
0.0 |
0.0 |
|
Income Available to Com Excl ExtraOrd |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
544.2 |
544.2 |
544.2 |
544.2 |
544.2 |
|
Basic EPS Excluding ExtraOrdinary Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Basic EPS Including ExtraOrdinary Item |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Dilution Adjustment |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
117.9 |
104.9 |
129.1 |
148.3 |
60.7 |
|
Diluted Weighted Average Shares |
544.4 |
544.6 |
544.2 |
544.3 |
544.3 |
|
Diluted EPS Excluding ExtraOrd Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
Diluted EPS Including ExtraOrd Items |
0.22 |
0.19 |
0.24 |
0.27 |
0.11 |
|
DPS-Common Stock |
0.00 |
0.26 |
0.00 |
0.25 |
0.00 |
|
Gross Dividends - Common Stock |
0.0 |
140.8 |
0.0 |
133.4 |
0.0 |
|
Normalized Income Before Taxes |
201.2 |
148.8 |
217.1 |
253.4 |
187.6 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
83.7 |
66.7 |
50.5 |
87.3 |
86.0 |
|
Normalized Income After Taxes |
117.5 |
82.1 |
166.6 |
166.0 |
101.6 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
115.0 |
78.7 |
163.7 |
161.7 |
99.0 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
0.21 |
0.14 |
0.30 |
0.30 |
0.18 |
|
Diluted Normalized EPS |
0.21 |
0.14 |
0.30 |
0.30 |
0.18 |
|
Sales Promotion |
34.9 |
75.4 |
51.7 |
39.5 |
35.6 |
|
Research&Development |
164.8 |
189.1 |
183.8 |
170.5 |
158.4 |
|
Interest Expense |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Depreciation |
43.9 |
58.4 |
53.4 |
41.6 |
46.6 |
|
Reported Operating Profit |
209.8 |
160.6 |
190.6 |
240.5 |
189.2 |
|
Reported Ordinary Profit |
205.8 |
162.0 |
191.3 |
238.9 |
202.9 |
|
|
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
|
|
|
|
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
31-Dec-2007 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
76.94 |
81.105 |
93.095 |
90.65 |
111.715 |
|
Auditor |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified with
Explanation |
|
|
|
|
|
|
|
|
Cash & Deposit |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
654.9 |
|
Acc.& Note Rcvbl. |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
957.9 |
|
Marketable Secs. |
792.8 |
736.1 |
560.3 |
603.6 |
586.7 |
|
Inventories |
- |
- |
- |
- |
494.0 |
|
Inventories - merchandise&finished goods |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
- |
|
Inventories - work-in-process |
0.3 |
0.2 |
0.1 |
0.6 |
- |
|
Inventories - raw materials&supplies |
230.3 |
190.1 |
224.8 |
187.4 |
- |
|
Deferred Inc. Tax |
295.6 |
245.7 |
226.2 |
240.9 |
183.2 |
|
Other Cur. Asset |
164.2 |
153.2 |
181.5 |
109.2 |
75.9 |
|
Allow Doubt. Acc. |
0.0 |
-0.1 |
-0.4 |
-0.7 |
-0.5 |
|
Total Current Assets |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
2,952.2 |
|
|
|
|
|
|
|
|
Buildings & Structures |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
969.2 |
|
Depreciation - Buildings & Structures |
-938.0 |
-932.0 |
-759.8 |
-746.1 |
-562.2 |
|
Machinery, Equip. & Vehicles |
1,099.8 |
1,075.1 |
899.6 |
835.5 |
613.4 |
|
Depreciation - Machi., Equip. & Vehicles |
-892.8 |
-838.5 |
-662.9 |
-602.6 |
-446.8 |
|
Tools, Furniture & Fixtures |
543.6 |
497.0 |
406.8 |
389.4 |
301.8 |
|
Depreciation - Tools, Furniture & Fix. |
-462.5 |
-416.4 |
-334.1 |
-317.9 |
-243.6 |
|
Land |
132.3 |
122.0 |
106.3 |
109.6 |
88.9 |
|
Constr. In Progr. |
35.3 |
24.8 |
16.4 |
60.5 |
107.3 |
|
Other, prop., plants, & equip., gross |
0.8 |
0.6 |
0.2 |
0.0 |
- |
|
Accum. depr - other PPE |
-0.3 |
-0.2 |
0.0 |
0.0 |
- |
|
Software |
4.3 |
7.9 |
11.3 |
27.2 |
23.7 |
|
Other Intangible |
21.2 |
21.2 |
23.5 |
7.0 |
9.6 |
|
Investment Secs. |
82.8 |
92.8 |
103.7 |
158.7 |
150.7 |
|
Investment Secs.-stock |
0.8 |
0.7 |
- |
- |
- |
|
LT Loans |
0.1 |
0.2 |
0.3 |
0.5 |
0.6 |
|
Deferred Income Tax |
182.4 |
184.2 |
156.8 |
134.6 |
80.5 |
|
Other Assets |
115.1 |
108.5 |
88.9 |
69.6 |
65.1 |
|
Allow Doubt Acc. |
-2.2 |
-2.3 |
-2.4 |
-2.5 |
-2.2 |
|
Translatn. Adjust |
- |
- |
- |
- |
0.0 |
|
Total Assets |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
4,108.1 |
|
|
|
|
|
|
|
|
Acc.& Note Payab. |
225.5 |
240.3 |
368.0 |
317.3 |
155.1 |
|
Cur. Corp. Bond |
- |
- |
- |
0.0 |
2.7 |
|
Cur.Convert. Bond |
- |
- |
- |
0.0 |
0.4 |
|
Current lease obligations |
- |
- |
0.1 |
0.0 |
- |
|
Other Payable |
102.5 |
73.2 |
70.9 |
77.8 |
46.6 |
|
Inc. Tax Payable |
184.0 |
45.4 |
237.8 |
125.5 |
146.1 |
|
Deferred Inc. Tax |
- |
- |
- |
0.0 |
0.0 |
|
Consumption taxes payable |
22.0 |
6.5 |
44.7 |
3.0 |
10.4 |
|
Accrued Expenses |
242.9 |
200.1 |
245.9 |
227.8 |
157.9 |
|
Allow for Bonus |
68.6 |
56.6 |
61.6 |
48.5 |
40.6 |
|
Allow for Director's Bonus |
2.4 |
2.7 |
1.9 |
2.3 |
1.8 |
|
Returned Goods |
- |
- |
- |
- |
0.0 |
|
Allowance for loss on disaster |
0.8 |
0.0 |
- |
- |
- |
|
Provision for environmental measures |
0.4 |
0.0 |
- |
- |
- |
|
Sales Discount & Other |
25.8 |
30.0 |
32.7 |
42.5 |
36.6 |
|
Other Cur. Liabs |
19.5 |
18.3 |
15.7 |
21.4 |
26.7 |
|
Total Current Liabilities |
894.4 |
672.9 |
1,079.3 |
866.2 |
624.7 |
|
|
|
|
|
|
|
|
Corp. Bond |
- |
- |
- |
- |
0.0 |
|
Convertible Bond |
- |
- |
- |
- |
0.0 |
|
Lease obligations |
- |
- |
0.1 |
0.0 |
- |
|
Total Long Term Debt |
- |
- |
0.1 |
0.0 |
0.0 |
|
|
|
|
|
|
|
|
Deferred tax liabilities |
1.4 |
0.0 |
|
|
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.92 |
|
|
1 |
Rs.86.03 |
|
Euro |
1 |
Rs.69.13 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.